Table Of Content

AUTHOR INDEX Arthritis Care & Research, Volume 49, Numbers 1-6, 2003 A Brown L, 819 Dinant HJ, 567 Govoni M, 145 Bruet A, 93 Doran MF, 216 Grambow SC, 619 Abasolo L, 64 Brun JG, 187 Dorner T, 546 Gravallese EM, 149 Agard C, 709 Brunner HI, 335 Downs L, 394 Griffin K, 689 Albrecht A, 546 Buckley L, 732 Doyle J, 59 Groessl EJ, 23 Alderdice J, 617 Buratti S, 501 Duarte-Salazar C, 501 Gromnica-Ihle E, 314 Alexiades-Armenakas MR, Burckhardt CS, S96 Dueymes M, 804 Guerrero J, 388 494 Burmester GR, 546 Dunlop DD, 101, 121, 164 Guillevin L, 93, 633, 709, 819 Allaire SH, S85 Bush TM, 810 Dupond JL, 633 Guis S, 237 Allison J, 293 Bystryn JC, 494 Dyer A, 300 Gummesson C, 697 American College of Gwilliam PDH, 689 Rheumatology Ad Hoc E Gyurcsik NC, 306 Committee on Immunologic Cc Testing Guidelines, 399 Edmonds J, 29 Anaya JM, 738 Cadd WT, 16 Egerer K, 546 H Cadena J, 738 Anderson DL, 148 Eisen SA, 745 Callahan LF, 51, 658, 724 Hagen LE, 3 Anderson LA, 51 Ekdahl C, 681, 697 Cantini F, 541 Hakkinen A, 71, 789 Anderson RJ, 421 Elder ME, 862 Carmona L, 64 Hakkinen K, 789 Andre MH, 633 El-Hajj I, 737 Carr A, $113 Halse Jl, 355 Ansart S, 804 Emery HM, 862 Catanoso MG, 541 Hamidou H, 93 Anthony KK, 272 Escalante A, 200 Cavazzini L, 145 Ham SA, 129 Appelboom T, 142 Estabrooks PA, 306 Chamberlain MA, 349 Handwerger BS, 16 Aréne JP, 93 Ettinger WH, 453 Chan A, 526 Hannonen P, 71, 789 Ariza-Ariza R, 483 Evidence-Based Medicine Chan C, 526 Hanson KD, 766 Arlaud J, 633 Working Groups in Chang RW, 101, 164, 280 Hara M, 784 Armesto V, 737, 741 Rheumatology, 377, 574 Chan KM, 526 Harms-Ringdahl K, 321 Arroliga AC, 151 Eyler AA, 136, 141 Chen T, 328 Harrington JT, 716 Arroyo RA, 200 Chiou CF, 78, 798 Harrison MJ, 846 Association of Rheumatology Chiu P, 526 F Harrold E, 826 Health Professionals Christoforov B, 633 Harth M, 144 Outcomes Measures Task Falch JA, 355 Chuzhin Y, 617 Harvey A, 349 Force, S15 Fang MA, 745 Atroshi I, 697 Cid MC, 819 Farraye FA, 614 Hashimoto H, 594, 867 Cipriani J, 640 Haugeberg G, 209, 355 Feist E, 546 Clark A, 239 Hayes KW, S28 B Feldman BM, 3, 335 Clark DO, 179 Fifield J, 368, 740 Hazes JMW, 193, 665 Badamgarav E, 377 Clements M, 843 Figarella-Branger D, 237 Heijmans M, 838 Baldassano M, 494 Cohen P, 93 Finch W, 745 Hellmann DB, 819 Bartlett SJ, 778 Corbo JC, 614 Fischbach M, 200 Helmick CG, 129 Bathon JM, 778 Cordier JF, 93 Fitzgerald O, 221 Hernandez-Garcia B, 483 Battafarano DF, 200 Courtney PA, 617 Flores RH, 16 Hernandez-Garcia C, 64 Baty V, 633 Cozzone PJ, 237 Flor H, 314 Hernandez-Rodriguez J, 819 Beach S, 640 Criscione LG, 361 Fortune DG, 689 Herrero-Beites A, 736 Bellajdel B, 64 Croft JD Jr., 377, 574 Fossel AH, 156 Herrick AL, 689 Bendahan D, 237 Cronan TA, 23 Fox A, 640 Hertzer J, 546 Berger ML, 508 Crosbie J, 29 Fox PC, 585 Herzog W, 239, 261 Bergink AP, 648 Crowson CS, 216 Frahm-Templar MJ, 306 Hesselbrock V, 368, 740 Beristain-Manterola R, 501 Cummings SR, 752 Franks AG Jr., 494 Hewett JE, 549, 766 Bernard V, 237 Cummins MJ, 585 Fransen J, S214 Hewlett S, 281 Bernsen RMD, 228 Cunningham F, 745 Fransen M, 29 Hjortdahl P, 342 Bernstein B, 501 Currey SS, 51, 658 Freburger JK, 51 Hochberg MC, 752 Bierma-Zeinstra SMA, 228 French Vasculitis Study Hoffman GS, 151, 819 Bilderback A, 778 D Group, 93 Hofman A, 648 Bince B, 494 Furst DE, 574 Hohlbauch A, 377, 574 Blanche P, 633 Damush TM, 179 Hgiseth A, 355 Bode RK, 7 D’Arbonneau F, 804 G Holm MB, 640 Boiardi L, 541 Da Silva E, 216 Hootman JM, 122, 129, 141 Boissonnas A, 633 DeFriese GH, 724 Gabriel SE, 703 Hunder GG, 149, 703 Bombardier C, 335 Degotardi P, S105 Garcia-Porrua C, 388, 737, Hung YY, 752 Boonman DCG, 665 de Jong Z, 665 741, 866 Hunt IM, 519 Borenstein J, 78, 798 Dekker J, 838 Gelber AC, 85 Hurley MV, 444, 453 Boshuizen HC, 567 Dellaripa PF, 819 Gelfand SG, 144, 618 Boutaugh ML, 463, 477 Del Rincén I, 200 Gerloni V, 501 I Bowyer S, 300 Desvaux A, 633 Giasi V, 147 Bozzola E, 488 Detournay B, 633 Gilson B, 93 Inaba Y, 594, 867 Brady TJ, 471, 477, S147 DeVellis BM, 724 Gilworth G, 349 Inman RD, 479 Brandt KD, 267, 280 DeVellis RF, 724 Gollish JD, 535 Irrgang JJ, S67 Breedveld FC, 193 Dhote R, 633 Gonzalez-Gay MA, 388, 737, Irvin WS, 766 Brekke M, 342 Dijkmans BAC, 209 741, 866 Isenberg DA, S225 Bresnihan B, 221 Dimachkie MM, 172 Gonzalez-Juanatey C, 866 Iversen MD, S210 Lechman TS, 7 Munneke M, 665 Lee P, 526 Murphy FT, 200 Jacobi CE, 567 Lefevre P, 722 Mutran EJ, 724 Qi R, 179 Jacobsson LTH, 681 Lems WF, 209 Jalava J, 328 Liang MH, 156, 574, 720 R Jamison M, 673 Lidov HGW, 421 N Jansen A, 665 Lietsalmi AM, 71 Ramsey-Goldman R, 300, Jenckes MW, 819 Lievense AM, 228 Naglie G, 283 $225 Jette AM, 114, 121 Lilleadse F, 355 Nahit ES, 519 Rao JK, 179, 619, 658 Johnson GE, 766 Lipton R, 300 Nakajima N, 594 Rapoff MA, S90 Johnson ME, S28 Llorca J, 388 Nakayama T, 594 Rasker JJ, 556 Johnson RW, 172 Lodder MC, 209 Navarro-Sarabia F, 483 Ravelli A, 488, 501 Johnsson R, 697 Lo Scocco G, 541 Neuberger GB, 673, S175 Reiff A, 501 Johnston SK, 766 Lotstein D, 810 Neuwelt CM, 810 Reisine S, 368, 740 Jones KD, S96 Louie JS, 377 Nevitt MC, 752 Reveille JD, 172, 399 Jonsson R, 187 Loukes J, 689 NIAMS Juvenile DM Registry Richards HL, 689 Jordan JM, 724 Lubeck DP, 78, 798 Physician Referral Group, Riemsma RP, 556 Jover JA, 64 Lu TT, 862 300 Rimpildinen M, 328 Juarez L, 293 Luukkainen R, 328 Niccoli L, 541 Ritter J, 617 Nielson W, 144 Roberts WN, 843 Lyyski T, 789 K Niles JL, 151 Rodriguez-Ledo P, 388 Nuenninghoff DM, 858 Roettcher P, 300 Kalappa N, 16 M Numano F, 594 Rogers JC, 640, S67 Kamatani N, 784 Nyman K, 789 Ronday HK, 665 Kamino H, 494 Macchioni P, 541 Rosen A, 85 Kammer GM, 585 Macera CA, 122, 129, 141 Rosenstein ED, 617 Kaplan RM, 23 Macfarlane GJ, 519 O Roth EA, 508 Katz JN, 156, S43 Machold KP, 626 O'Dell J, 377 Rothfield N, 368, 740 Katz P, 377 Maclean CH, 508 O’Fallon WM, 216, 703 Roubenoff R, 263, 280 Katz PP, S1, S15 Madland TM, 187 Ofman JJ, 78, 377, 508, 574, Roudier J, 722 Kaufman L, 617 Maeno N, 501 798 Rubin HR, 819 Kautiainen H, 71 Maetzel A, 283 Ohno Y, 594, 867 Rudolph PE, 546 Kawamura T, 594, 867 Magni-Manzoni S, 488 Olivieri I, 147, 541 Ruggieri AP, 853 Kazi S, 172 Mahr A, 93, 709 Olivieri J, 293 Ruivard M, 93 Kennedy D, 535 Maldonado-Velazquez MR, Orces C, 703 Ruperto N, 488, 5014 Keyser RE, 16 501 Ornstein E, 697 Rupp I, 567 Keysor JJ, 114, 724 Manana P, 741 @rstavik RE, 209, 355 Russak SM, 78, 574, 798 Kim LH, 605 Manheim LM, 101, 164 Ostbye T, 144 Russell A, 142 Kissin EY, 614 Mann JA, 599 Rus V, 16 Klassbo M, 321 Manthorpe R, 681 Klein-Gitelman MS, 7 Martens MP, 549 P Klepper SE, 435, 453, S5 Martini A, 488, 501 Kobayashi S, 594, 867 Matsuda Y, 784 Pacheco-Tena C, 479 Saag KG, 293 Koes BW, 228 Matsumoto AK, 778 Pachman LM, 7, 300 Sailler L, 633 Komatireddy GR, 766 Matsumoto Y, 594, 867 Padula A, 147, 541 Saito T, 784 Konrad TR, 724 Mattei JP, 237 Pagura SMC, 535 Salisbury D, 745 Kooiman KG, 193 Matteson EL, 216, 858 Papas A, 585 Salvarani C, 541 Korn JH, 605 Maver J, 280 Papo T, 633 Sandborg CI, 759 Kostense PJ, 209 Mayer ML, 759 Parent E, 36 Sanders L, 361 Koutantji M, 826 McClure P, S50 Parker JC, 549, 766 Sangha O, 156 Kovac SH, 293 McGibbon CA, 248, 261 Patino FG, 293 Saulsbury FT, 599 Kozak-Ribbens G, 237 McQuillan J, 368, 740 Paulus HD, 78, 574, 798 Scarano E, 147 Krahn M, 283 Mechenstock D, 633 Pearce S, 826 Scarborough DM, 248 Kramer N, 617 Meenan R, 477 Pego-Reigosa R, 737 Schaeffer A, 633 Krebs DE, 248, 261 Mellins ED, 759 Pellissier JF, 237 Schanberg LE, 272, 280 Kroenke K, 619 Mendez EP, 300 Pennec YL, 804 Schiaffino KM, S165 Kujawska A, 843 Merkel PA, 151, 614, 819 Perez-Ruiz F, 736 Schneider R, 3 Kvien TK, 209, 342, 355 Michener L, S50 Perkins SM, 179 Schulz R, 640 Kwok T, 526 Mihaliak KA, 619 Person S, 293 Schumacher HR Jr., 413 Mikuls TR, 293 Pertuiset E, 93 Schuster SJ, 394 L Miller ML, 7 Peter WFH, 665 Schwab P, 421 Miller P, 673 Piedmont R, 778 Schwartz RB, 421 Labussiere AS, 633 Minnock P, 221 Piette AM, 633 Scott DGI, 826 Lajas C, 64 Minor MA, 1, 428, 453 Piette JC, 633 Sengupta N, 78, 798 Lam D, 526 Moadel AB, 78, 798 Pincus T, 59 Sharma L, 255, 261 Lando A, 237 Modrusan D, 3 Pisetsky DS, 149, 361 Sharpe PA, 455, 477 Lane NE, 752 Moffet H, 36 Pistorio A, 488, 501 Sheehan TJ, 368, 740 Lane SE, 826 Mol GD, 567 Ploner A, 626 Shekelle PG, 508 Lanoux P, 93 Moncur C, S197 Pols HAP, 648 Shepherd R, 745 Larroche C, 633 Moreland L, 293, 574, 819 Poole JL, S59 Sherbourne CD, 78, 798 Larsson G, 321 Morton SC, 508 Poullin P, 722 Silman AJ, 519 Lau CS, 526 Mottonen T, 328 Pratsidou-Gertsi P, 501 Silverman ED, 335 Lau E, 526 Mouthon L, 93, 709 Priesmeyer ML, 766 Simkin PA, 735 Lazaro P, 64 Mudano A, 293 Proven A, 703 Simon J, 633 Le Berre R, 804 Mugnier B, 722 Puéchal X, 93 Simon LS, 574 890 Singh G, 784 Sundaramurthy S, 810 Ulanet DB, 85 Weinstein B, 394 Singh JA, 745 Urano W, 784 Weisman MH, 78, 574, 798 Siva C, 745 T Uthman I, 737 Werth V, 494 Slaughter JR, 549, 766 Whitehead EM, 617 Smarr KL, 549, 766, S134 Taal E, 556 V White KP, 144 Smith J, 349 Taher A, 737 White P, 377 Smith MT, S184 Takei S, 501 Vainio O, 328 Wigley FM, 85 Smolen J, 626 Tamakoshi A, 594, 867 van den Bos GAM, 567 Williams EN, 752 Smyth MG, 349 Tanaka E, 784 van den Ende CHM, 665 Williams FM, 172 Sniezek JE, 122, 129, 141, 471 Taniguchi A, 784 Van Der Esch M, 838 Winfield JB, 658 Sokka T, 71 Taylor S, 519 van der Klift M, 648 Wise CM, 843 Solomon DH, 399 Tennant A, 349 Vanhille P, 93 Wolfe F, 59 Somer BG, 394 Tennen H, 368, 740 van Leeuwen JPTM, 648 Woodhouse A, 349 Song J, 101, 164 Testa A, 866 van Riel PLCM, S214 Woo J, 526 Soter NA, 494 Thieme K, 314 Vargas E, 64 Woolf AD, 209 Speechley M, 144 Thompson AK, 59 Vassilopoulos D, 151 Wu J, 239 Spencer CH, 501 Tierney WM, 179 Verhaar JAN, 228, 648 Spiera R, 819 Tijhuis GJ, 193 Verhagen AP, 228 Y Stamm TA, 626 Toivanen P, 328 Villa-Forte A, 151 Yamanaka H, 784 Starz TW, 640 Tomatsu T, 784 Viola S, 488 Yano T, 594, 867 St.Clair EW, 361 Towheed TE, 601 Vliet Vlieland TPM, 193, 665 Yasuda K, 594 Stenstr6m CH, 428, 453 Traboulsi R, 737 Von Scheven E, 862 Yelin EH, 101, 121 Stephens D, 3 Treffouret S, 237 Yli-Jama T, 328 Stern R, 745 Trotta F, 145 Ww Youinou P, 804 Stone JH, 819 Tsai DE, 394 Yutani C, 594 Stratford PW, 535 Tsitsami E, 488 Walker SE, 549, 766 Straus WL, 508 Tugwell P, 574 Wara DW, 862 Z Street RL Jr., 810 Ward MM, 810 Strombeck B, 681 U Warrington KJ, 858 Zarabadi SA, 745 Stucki G, 156, S214 Watts RA, 826 Zhang J, 526 Suarez-Almazor ME, 377 Uhlfelder ML, 819 Weaver A, 377 Zhang X, 479 Sugarman J, 361 UhlT,i 209g, 3 55 Wegener ST, $184 Ziza JM, 633 Sullivan EJ, 151 Jitterlinden AG, 648 Weinberger M, 179, 619 Zwinderman AH, 193, 665 SUBJECT INDEX Arthritis Care & Research, Volume 49, Numbers 1—6, 2003 A Arthritis (cont’d) physical activity levels in US population with and without Access to care, pediatric rheumatology care in US, access to, 759 arthritis, 129 Activities of daily living (ADL) rehabilitation perspectives on compensatory mechanics in gait, disability assessment using performance in the home, concor- 248 dance of methods, 640 self-management strategy use, 724 RA, falls and fear of falling and, 673 See also Rheumatoid diseases; specific types of arthritis Activities of Daily Living Scale of the Knee Outcome Survey Arthritis Foundation, community-based physical activity pro- (ADLS), S67 grams, 463 Acute low back pain (ALBP), self-management program for, 179 Arthritis Hand Function Test (AHFT), S59 Adherence. See Treatment adherence Arthritis Helplessness Index (AHI)/Rheumatology Attitudes In- Adverse events, dyspepsia and NSAIDs, meta-analysis, 508 dex (RAI), S147 Aerobic capacity Arthritis Impact Measurement Scales (AIMS/AIMS2), S113 exercise and physical activity in children, benefits of, 435 Arthritis Self-Efficacy Scale (ASES), S147 SS, physical capacity in, 681 Arthroplasty, preoperative predictors of locomotor ability follow- Aerobic exercise, RA, benefits of, 428 ing total knee arthroplasty, 36 Aerobic insufficiency, SLE, women with, 16 Aspiration, for joints, 413 Affect Balance Scale (ABS), S165 Assessment Affective disorder, RA, receiver operator characteristic analysis, of adult back and neck function, S43 368 of adult general functional status, $15 African American population, RA, ethnic variation in clinical of adult general performance tests, S28 manifestations, HLA-DRB1 alleles and, 200 of adult hand function, S59 Alternative medicine. See Complementary and alternative medi- of adult lower extremity function, S67 cine of adult measures of pain, S96 American Academy of Orthopedic Surgeons Lower Limb Ques- of adult quality of life, S113 tionnaire, S67 of adult shoulder function, S50 American College of Rheumatology (ACR), new policy on disclo- of adult work disability, S85 sure of interest for journals, 149 AS measures, S197 American Shoulder and Elbow Surgeons Standardized Shoulder of depression and depressive symptoms, 368, 549, S134 Form, S50 of disability, using performance in the home, 640 Amyloid deposits, cerebral amyloid angiopathy associated with of fatigue, S113, $175 primary angiitis of the nervous system, 2 case reports, 421 FM measures, $210 Aneurysm, concomitant giant cell aortitis, thoracic aortic aneu- innovation in capturing data about functional status, 853 rysm, and aortic arch syndrome, 858 juvenile-onset SLE, organ damage in, 501 Ankylosing spondylitis (AS) OA, content validity of timed tests, 535 measures of, 483, S197 pediatric function, S5 physical function and health-related quality of life in, 483, $197 pediatric measures of pain, S90 Ankylosing Spondylitis Quality of Life (ASQOL), S197 pediatric measures of quality of life, S105 Anti-Scl-70 autoantibodies, SSc, guidelines for immunologic test- of psychological well-being, S134, S147, S165 ing, 399 Quality of Well-Being Scale, 23, $113 Anti-transforming growth factor f (anti-TGF-£), treatment for skin RA, depression in, 549 and lung fibrosis in murine sclerodermatous graft-versus-host RA, health-related quality of life patient questionnaires in clin- disease, 611 ical practice, 574 Anticentromere autoantibodies, SSc, guidelines for immunologic RA, quality of life related to social support and disease knowl- testing, 399 edge in women, 221 Anticholesterolemic treatment, rhabdomyolysis and myalgia RA, self-report questionnaires in clinical practice, 59 with, malignant hyperthermia susceptibility and, 237 RA measures, S96, S214 Antidepressants, depression in RA, combined pharmacologic and of self-efficacy, helplessness, mastery, and control, S147 cognitive-behavioral approach, 766 SLE measures, S225 Antineutrophil cytoplasmic antibodies (ANCA), in diseases that sleep measures, S184 mimic systemic vasculitides, 151 See also Measuring instruments Antinucleolar antibodies (ANA), SSc, guidelines for immunologic Assistive devices, RA and OA, walking aids, possession and use testing, 399 of, 838 Anxiety Atorvastatin, rhabdomyolysis and myalgia with, malignant hyper- measures of psychological well-being, S134, S165 thermia susceptibility and, 237 RA, receiver operator characteristic analysis of affective disor- Autoantibodies, against B23 in SSc, associated with pulmonary der in, 368 hypertension, 85 Aortic aneurysm, concomitant giant cell aortitis, thoracic aortic B aneurysm, and aortic arch syndrome, 858 Aquatic exercise, in arthritis, 306 B23, autoantibodies associated with pulmonary hypertension, 85 Arthritis Back function, measures of, S43 aquatic exercise in, 306 Back pain consent to research: quantity of information versus quality, 281 acute low back pain (ALBP), self-management program for, 179 correlates of physical activity, 136 measures of, S43 cost of, 101 Bacteria, in RA or OA, 328 exercise and physical activity in children, benefits of, 435 Balance, Berg Balance Scale, S28 health care utilization among older adults with, 164 Barthel Index, S15 inflammatory disease and exercise, 263 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Moberg pickup test, 626 S197 892 Bath Ankylosing Spondylitis Functional Index (BASFT) Comorbidity overview, S197 coxibs, use and discontinuation influenced by, 293 reliability of Spanish version of, 483 Self-Administered Comorbidity Questionnaire (SCQ), 156 Bath Ankylosing Spondylitis Global Score (BAS-G), S197 Complementary and alternative medicine Bath Ankylosing Spondylitis Metrology Index (BASMI), S197 for pediatric patients, 3 Beck Depression Inventory (BDI), $134 use by rheumatology patients: one-year study, 619 Behavior therapy, FM, operant behavioral treatment, 314 Control, measures of, S147 Behavioral Risk Factor Surveillance System (BRFSS), health-re- Costs. See Medical costs; Pharmacoeconomics lated quality of life measure, 658 Cyclooxygenase 2 (COX-2) inhibitors Behcget’s disease, infliximab treatment for child, 599 cost effectiveness of rofecoxib and celecoxib in OA or RA, 283 Berg Balance Scale, S28 use and discontinuation of, physician specialty and patient Bible, did Moses inherit SpA, 142 comorbidities and, 293 Biopsy, SS, risk factors for positive minor salivary gland biopsy Cyclophosphamide, for polyarteritis nodosa and microscopic findings in, 145 polyangiitis with poor prognosis, 93 Bone mineral density (BMD) hip OA, nitrate medication use and new radiographic findings in older women, 752 D RA, damage associated with low BMD and vertebral deformi- Data collection, innovation in capturing data about functional ties, OSTRA Study, 209 status, 853 RA, vertebral deformities in women and, 355 Day patient care, RA, validation of satisfaction questionnaire for, Bosentan therapy, SSc, pulmonary arterial hypertension in, 608 193 British Isies Lupus Assessment Group (BILAG), S225 Depression Button test, comparison of Moberg pickup test with, 626 measures of, 368, 549, S134 RA, assessment of in, 549 Cc RA, combined pharmacologic and cognitive-behavioral ap- proach, 766 Caregivers, RA, quality of life related to social support and disease RA, receiver operator characteristic analysis of affective disor- knowledge in women, 221 der in, 368 Cedars-Sinai Health-Related Quality of Life Instrument Dermatomyositis (DM) development of, 78 Disease Activity Score for juvenile DM, 7 validation of, 798 US incidence of juvenile DM: 1995-1998, 300 Celecoxib, cost effectiveness in OA or RA, 283 Disabilities of the Arm, Shoulder, and Hand (DASH), S50 Center for Epidemiological Studies Depression Scale (CES-D) Disability as measuring instrument, S134 AS, measures of, S197 RA, affective disorder in: receiver operator characteristic ana- assessment of using performance in the home, 640 lysis, 368 chronic upper extremity pain and co-occurring symptoms, 697 RA, depression in, 549 disability models, 114 Cerebral amyloid angiopathy, associated with CNS primary angi- FM, assessment of, S210 itis, 2 case reports, 421 measures of adult back and neck function, S43 CES-D, 368, 549, S134 measures of adult hand function, S59 Chapel Hill Consensus Conference definitions, primary systemic measures of adult lower extremity function, S67 vasculitides in Spain, epidemiology, 388 measures of adult quality of life, S113 Child Health Assessment Questionnaire (CHAQ), S5 measures of adult shoulder function, S50 Children measures of adult work disability, S85 access to pediatric rheumatology care in US, 759 measures of depression and depressive symptoms, S134 Behcet’s disease, infliximab treatment, 599 measures of pain, S96 complementary and alternative medicine used by, 3 measures of psychological well-being, S134, S147, S165 exercise and physical activity in children with arthritis, benefits pediatric measures of pain, S90 of, 435 pediatric measures of quality of life, S105 measures of pediatric function, S5 RA, measures of, S96, S214 measures of pain, S90 RA, strength training and disability in recent-onset RA, 71 measures of quality of life, S105 RA, Work Instability Scale, 349 measures of self-efficacy, helplessness, mastery, and control, RA and OA, possession and use of walking aids in, 838 S147 SLE, measures of, $225 pain in juvenile arthritis, 272, S90 Disease activity SLE, validation of ECLAM for, 335 childhood-onset SLE, validation of ECLAM and, 335 WG, risk of thrombosis, 862 juvenile DM, validity of Disease Activity Score, 7 Children’s Arthritis Self-Efficacy Scale (CASE), S147 primary systemic vasculitis, quality of life, psychological ad- Clinical Nurse Specialist, RA, validation of satisfaction question- justment and, 826 naire for, 193 Disease Activity Score (DAS) Clinical practice, RA, health-related quality of life patient ques- overview, S214 tionnaires used in, 574 validity for children with juvenile DM, 7 Clinical trials, informed consent process for RA treatment, 361 Disease course, RA, impact of socioeconomic status on course of, Cognitive-behavioral therapy, depression in RA, pharmacologic 567 approach combined with, 766 Disease knowledge, RA, quality of life related to, 221 Colchicine, myopathy in patient with familiar Mediterranean fe- Disease management programs, RA, functional status and, 377 ver, 614 Disease-modifying antirheumatic drugs (DMARDs), leflunomide Combination therapy, leflunomide for RA, safety of use, 745 for RA, safety of use, 745 Communication, SLE, participatory patient-physician communi- Disease Repercussions Profile (DRP), S113 cation and morbidity, 810 Dougados Functional Index (DF), $197 Community-based intervention Dry mouth. See Sicca symptoms Arthritis Foundation programs, 463 Dynamic exercise, RA, adherence with long-term intensive exer- National Arthritis Action Plan implementation, 471 cise (RAPIT Program), 665 physical activity intervention, 455, 463 Dynamic Gait Index (DGI), S28 Dyspepsia, NSAIDs and, meta-analysis, 508 Fibromyalgia (FM) (cont’d) operant behavioral treatment, 314 Trust in Physician Scale, use, 51 E Fibromyalgia Impact Questionnaire (FIQ), S210 Education. See Patient education Fibrosing alveolitis, SSc, outcome relationship to, 610 Elderly. See Older adults Fibrosis, SSc, anti-TGF-8 treatment in murine sclerodermatous Emotional distress, RA, receiver operator characteristic analysis graft-versus-host disease, 611 of affective disorder in, 368 Foot Function Index (FFI), S67 Endler Multidimensional Anxiety Scales (EMAS), RA, affective Forearm, predicting onset of pain in, 519 disorder in: receiver operator characteristic analysis, 368 Fractures Endurance training, RA, strength and endurance training (concur- fatigue fractures suggesting monarthritis, 741 rent) in, 789 hip OA, nitrate medication use and new radiographic findings Epidemiology in hip OA in older women, 752 forearm pain, predicting onset, 519 knee OA, vertebral and nonvertebral fractures in the elderly, GCA in Japan, 594 648 juvenile DM, US incidence 1995-1998, 300 osteoporosis update, 732 primary systemic vasculitides in Spain, 388 Functional assessment Errata, 148, 477, 740 AS measures, 483, S197 Ethics back and neck function, measures of, S43 informed consent process for clinical trial, 361 depression and depressive symptoms, measures of, 5134 new disclosure of interest policy for ACR journals, 149 disability assessment using performance in the home, 640 Ethnicity, RA, role of HLA-DRB1 alleles in clinical manifestations fatigue, measures of, S113, $175 of, 200 FM measures, S210 European Consensus Lupus Activity Measurement (ECLAM) general functional status, measures of, S15 childhood-onset SLE, validation in, 335 general performance tests, S28 overview, S225 hand function, measures of, S59 EuroQoL, $113 innovation in capturing data about functional status, 853 Exercise lower extremity function, measures of, S67 2002 Exercise and Physical Activity Conference, 1 Moberg pickup test, 626 aquatic exercise in arthritis, 306 pain, measures of, 590, S96 children with arthritis, benefits of, 435 pediatric function, measures of, S5 community-based intervention, Arthritis Foundation programs, pediatric measures of pain, S90 463 pediatric measures of quality of life, S105 community-based intervention, National Arthritis Action Plan psychological well-being, measures of, S134, S165 implementation, 471 RA measures, S96, S214 community-based physical activity intervention, 455, 463 quality of life, measures of, S105, S113 correlates of physical activity, 136 self-efficacy, helplessness, mastery, and control, measures of, disability models, implications for, 114 $147 inflammatory disease and, 263 SLE measures, S225 OA, exercise effects on knee OA outcome, mechanical environ- sleep measures, S184 ment and, 255 shoulder function, measures of, S50 OA, sporting activity and development of hip OA, 228 work disability, measures of, S85 physical activity levels in US population with and without See also Measuring instruments arthritis, 129 Functional Assessment System (FAS), S67 public health benefits of physical activity, 122 Functional outcome RA, adherence with long-term intensive exercise (RAPIT Pro- acute low back pain, self-management program, 179 gram), 665 OA, self-report and performance-related measures, relationship RA, benefit of aerobic and strengthening exercise, 428 between, 535 RA, strength and endurance training (concurrent) in, 789 Functional status, RA, disease management programs and, 377 SLE, aerobic insufficiency in women, 16 Work Group Recommendations: 2002 Exercise and Physical G Activity Conference (St. Louis), 121, 141, 261, 280, 453, 477 See also Physical activity Gait Exercise and Physical Activity Conference (St. Louis, 2002), Work assessment of, S28 Group Recommendations, 121, 141, 261, 280, 453, 477 locomotor ability following total knee arthroplasty, preopera- tive predictors, 36 F rehabilitation perspectives on compensatory mechanics in, 248 Gait Velocity test, S28 Falls, RA, falls and fear of falling and life activities, 673 Gas chromatography-mass spectrometry, OA or RA, bacterial Familial Mediterranean fever, colchicine myopathy in, 614 components in synovial tissue, 328 Families, RA, group education for patients and partners, 556 General Health Questionnaire (GHQ-12), S165 Family history, of psoriasis in oligoarticular JIA, 488 Generalized Self-Efficacy Scale (GSES), S147 Fatigue Generic health status, in rheumatic disease, 658 measures of, $113, $175 Genetics SLE, aerobic insufficiency in women, 16 RA, ethnic variation in clinical manifestations, HLA-DRB1 al- SS, physical capacity in, 681 leles and, 200 Fatigue fractures, suggesting monarthritis, 741 WG, risk of thrombosis and, 862 Fatigue Questionnaire, $175 Geriatric Depression Scale (GDS), S134 Fatigue Scale, S175 Giant cell arteritis (GCA) Fibromyalgia (FM) concomitant giant cell aortitis, thoracic aortic aneurysm, and generic health-related quality of life measure in clinic popula- aortic arch syndrome, 858 tion, 658 glucocorticoid therapy, 703 labeling: pros and cons, 144, 618 in Japan, clinical and epidemiologic analysis, 594 measure of, S210 neovascularization around the optic nerve in, 737 894 Giant cell arteritis (GCA) (cont’d) Immunohistochemical analysis, tumid LE, 494 quality of life aspects important to GCA patients, 819 Immunologic testing, SSc, guidelines for use of anticentromere, Glucocorticoids Scl-70, and nucleolar antibody testing, 399 for GCA, duration and adverse outcomes, 703 Index of Severity for Hip Osteoarthritis (ISH), S67 for polyarteritis nodosa and microscopic polyangiitis with poor Index of Severity for Knee Osteoarthritis (ISK), S67 prognosis, 93 Indomethacin, dyspepsia and, meta-analysis, 508 Glucosamine, for OA, current status, 601 Infectious agents Gouty arthritis, uric acid excretion, 735 in the joints, 479 Graft-versus-host disease, murine sclerodermatous graft-versus- OA or RA, bacterial components in, 328 host disease, anti-TGF-6 treatment of skin and lung fibrosis as Inflammatory disease, exercise, 263 model for human SSc, 611 Infliximab Grip Ability Test (GAT), S59 Behget’s disease, pediatric patient, 599 RA, MTX pneumonitis after initiation of therapy, 617 resistant PsA, efficacy in, 541 Informed consent, consent process for clinical trial, 361 Hand function Injection therapies, for joints, 413 measures of, S59 Insomnia Severity Index, S184 Moberg pickup test, 626 Instrumental activities of daily living (IADL), disability assess- Harris Hip Score (HHS), S67 ment using performance in the home, 640 Health Assessment Questionnaire (HAQ), S15, 784 Interferon (IFN) alfa, SS, oromucosal administration of, 585 Health Assessment Questionnaire for the Spondylarthropathies Interstitial lung disease, SSc, fibrosing alveolitis in and outcome, (HAQ-S), S197 610 Health care redesign, rheumatology practice, redesigning, 716 Intraarticular therapies, aspiration and injection therapies, 413 Health care utilization Isometric muscle force, knee OA, 29 older adults with arthritis, 164 RA, impact of socioeconomic status on disease course and use J of health care services, 567 Health status, RA, changes over 5 years, 342 Japanese populations, Stanford Health Assessment Question- Health-status questionnaires naire, validation of Japanese version, 784 RA, Cedars-Sinai Health-Related Quality of Life Instrument, 78, Jebsen Test of Hand Function, S59 798 Joint disease models, resultant and local loading in, 239 RA, health-related quality of life questionnaires, use in clinical Joint mobility, SS, physical capacity in, 681 practice, 574 Joint replacement RA, self-report questionnaires in clinical practice, 59 OA, preoperative predictors of locomotor ability following total Self-Administered Comorbidity Questionnaire (SCQ), 156 knee arthroplasty, 36 Helplessness, measures of, S147 OA, socioeconomic impact of in Hong Kong, 526 Hemophagocytosis, reactive hemophagocytic syndrome in sys- RA, declining use in, 216 temic disease, 633 Joint structures, response to immobilization and remobilization, Hepatitis B, severe RA with chronic hepatitis B, clinical improve- 267 ment with protein A immunoadsorption, 722 Joint surgery, RA, declining use in, 216 Hepatitis C, MTX and, 843 Joints Hip aspiration and injection therapies for, 413 Harris Hip Score (HHS), S67 joint structures, response to immobilization and remobilization, hip dysfunction, outcome of “hip school,” 321 267 Index of Severity for Hip Osteoarthritis (ISH), S67 Juvenile arthritis OA, nitrate medication use and new radiographic findings in measures of pain, S90 hip OA in older women, 752 measures of pediatric function, S5 OA, sporting activity and development of, 228 measures of quality of life, S105 Hispanic population, RA, ethnic variation in clinical manifesta- pain in children, 272, S90 tions, HLA-DRB1 alleles and, 200 Juvenile Arthritis Functional Assessment Report (JAFAR), S5 HLA-DRB1 alleles, RA, ethnic variation in clinical manifestations Juvenile Arthritis Functional Assessment Scale (JAFAS), S5 of, 200 Juvenile Arthritis Functional Status Index (JASI), S5 Hodgkin’s lymphoma, presenting as Tietze’s syndrome, 737 Juvenile Arthritis Quality of Life Questionnaire (JAQQ), S105 Hong Kong, socioeconomic impact of OA, 526 Juvenile dermatomyositis (DM) Hospital Anxiety and Depression Scale (HADS), 5134 Disease Activity Score for children, 7 Human immunodeficiency virus (HIV), HIV-associated PM, 172 US incidence 1995-1998, 300 Juvenile idiopathic arthritis (JIA), family history of psoriasis in oligoarticular JIA, 488 i Juvenile-onset systemic lupus erythematosus (SLE), organ damage Illness beliefs, SSc, patients’ perceptions of, 689 in, assessment, 501 Imaging Juvenile rheumatoid arthritis (JRA), pain in children with, 272 cerebral amyloid angiopathy associated with CNS primary an- giitis, 421 K enthesitis of SpA masquerading as Osgood-Schlatter disease, 147 Katz Index of Activities of Daily Living, S15 familial Mediterranean fever, colchicine myopathy in, 614 Kidneys OA, nitrate medication use and new radiographic findings in SSc, long-term outcomes of renal crisis, 607 hip OA in older women, 752 SSc, renal functional reserve impairment without clinical signs RA, damage associated with low BMD and vertebral deformi- of kidney involvement, 605 ties, OSTRA Study, 209 SSc, severe organ involvement in SSc with diffuse scleroderma, tumid LE, immunohistochemical classification criteria, 494 606 Immobilization, joint structures, response to, 267 Knee Immunoadsorption, severe RA with chronic hepatitis B, clinical arthroplasty, preoperative predictors of locomotor ability fol- improvement with protein A immunoadsorption, 722 lowing, 36 895 Knee (cont’d) Measuring instruments (cont’d) Knee Injury and Osteoarthritis Outcome Score (KOOS), S67 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), OA, exercise effects on outcome, mechanical environment and, S197 255 Bath Ankylosing Spondylitis Functional Index (BASFI), 483, OA, isometric muscle force measurement, 29 $197 OA, muscle dysfunction and effective rehabilitation, 444 Bath Ankylosing Spondylitis Global Score (BAS-G), S197 OA, vertebral and nonvertebral fractures in the elderly, 648 Bath Ankylosing Spondylitis Metrology Index (BASMI), S197 Knee Injury and Osteoarthritis Outcome Score (KOOS), S67 Beck Depression Inventory (BDI), S134 Knowledge of disease, RA, quality of life related to, 221 Behavioral Risk Factor Surveillance System (BRFSS), 658 Berg Balance Scale, S28 British Isles Lupus Assessment Group (BILAG), S225 L Cedars-Sinai Health-Related Quality of Life Instrument, 78, 798 Child Health Assessment Questionnaire (CHAQ), S5 Leflunomide, RA, safe use in clinical practice, 745 Children’s Arthritis Self-Efficacy Scale (CASE), S147 Life Satisfaction Index-A (LSI-A), S165 depression and depressive symptoms, 549, S134 Loading Disabilities of the Arm, Shoulder, and Hand (DASH), S50 joint structures, response to immobilization and remobilization, disability assessment using performance in the home, 640 267 Disease Activity Score (DAS), 7, S214 in models of joint disease, 239 OA, exercise effects on knee OA outcome, mechanical environ- Disease Repercussions Profile (DRP), S113 ment and, 255 Dougados Functional Index (DFI), $197 Local loading, joint disease models and, 239 Dynamic Gait Index (DGI), S28 Locomotor ability, following total knee arthroplasty, preoperative European Consensus Lupus Activity Measurement (ECLAM), predictors, 36 335, S225 Low back pain EuroQoL, S113 acute low back pain (ALBP), self-management program for, 179 fatigue, S113, S175 measures of back function, S43 Fatigue Questionnaire, $175 Lower extremity function, measures of, $67 Fatigue Scale, S175 Lungs. See Pulmonary disease Fibromyalgia Impact Questionnaire (FIQ), S210 Lupus erythematosus. See Systemic lupus erythematosus; Tumid FM measures, S210 lupus erythematosus Foot Function Index (FFI), S67 Lymphoma Functional Assessment System (FAS), S67 Hodgkin’s lymphoma presenting as Tietze’s syndrome, 737 Gait Velocity test, S28 SS, improvement in following rituximab therapy for marginal General Health Questionnaire (GHQ-12), S165 zone lymphoma, 394 Generalized Self-Efficacy Scale (GSES), S147 Geriatric Depression Scale (GDS), $134 Grip Ability Test (GAT), S59 M Harris Hip Score (HHS), S67 Health Assessment Questionnaire (HAQ), S15, 784 MACTAR Patient Preference Disability Questionnaire, $15 Health Assessment Questionnaire for the Spondylarthropathies Malignant hyperthermia, rhabdomyolysis and myalgia with anti- (HAQ-S), S197 cholesterolemic treatment as sign of susceptibility to, 237 Hospital Anxiety and Depression Scale (HADS), S134 Marginal zone lymphoma, SS, improvement in following ritux- Index of Severity for Hip Osteoarthritis (ISH), S67 imab therapy, 394 Index of Severity for Knee Osteoarthritis (ISK), S67 Mass spectrometry, OA or RA, bacterial components in synovial Insomnia Severity Index, S184 tissue, 328 Jebsen Test of Hand Function, S59 Mastery Scale, S147 Juvenile Arthritis Functional Assessment Report (JAFAR), S5 McGill Questionnaire (MPQ), S96 Juvenile Arthritis Functional Assessment Scale (JAFAS), S5 Measurement, of isometric muscle force by clinicians in knee OA, Juvenile Arthritis Functional Status Index (JASI), S5 29 Juvenile Arthritis Quality of Life Questionnaire (JAQQ), S105 Measuring instruments juvenile DM, validity and reliability of Disease Activity Score Activities of Daily Living Scale of the Knee Outcome Survey for children, 7 (ADLS), S67 Katz Index of Activities of Daily Living, S15 adult back and neck function, S43 adult general functional status, $15 Knee Injury and Osteoarthritis Outcome Score (KOOS), S67 adult general performance tests, S28 Life Satisfaction Index-A (LSI-A), S165 adult hand function, S59 MACTAR Patient Preference Disability Questionnaire, S15 adult lower extremity function, S67 Mastery Scale, $147 adult measures of pain, S96 McGill Questionnaire (MPQ), S96 adult quality of life, S113 Medical Outcomes Study (MOS) Sleep Scale, $184 adult shoulder function, S50 Modified Health Assessment Questionnaire (MHAQ), S15 adult work disability, S85 Multi-Dimensional Health Locus of Control Scale (MHLC), Affect Balance Scale (ABS), S165 $147 American Academy of Orthopedic Surgeons Lower Limb Ques- Multidimensional Assessment of Fatigue Scale, $175 tionnaire, S67 NASS Lumbar Spine Outcome Assessment Instrument, S43 American Shoulder and Elbow Surgeons Standardized Shoul- Neck Disability Index, S43 der Form, S50 Nottingham Health Profile, $113 Ankylosing Spondylitis Quality of Life (ASQOL), $197 OA, content validity of timed tests, 535 Arthritis Hand Function Test (AHFT), S59 OA, Quality of Well-Being Scale, 23 Arthritis Helplessness Index (AHI)/Rheumatology Attitudes In- Oswestry Low Back Pain Disability Index, S43 dex (RAI), S147 Pain Behavior Observation Method, S90 Arthritis Impact Measurement Scales (AIMS/AIMS2), S113 Pain Coping Questionnaire (PCQ), S90 Arthritis Self-Efficacy Scale (ASES), $147 Parent’s Arthritis Self-Efficacy Scale (PASE), S147 AS measures, 483, S197 Patient Generated Index (PGI), S113 Barthel Index, S15 for pediatric function, S5 896 Measuring instruments (cont’d) Measuring instruments (cont’d) Pediatric Orthopedic Surgeons of North America (POSNA) Pe- Verbal Descriptive Scale (VDS), S96 diatric Musculoskeletal Functional Health Questionnaire, S5 Visual Analog Scale (VAS), S96 Pediatric Pain Questionnaire (PPQ), S90 West Haven-Yale Multidisciplinary Pain Inventory (WHYMP)I), Pediatric Quality of Life (PedsQL), $105 S96 Physical Performance Test (PPT), S28 Western Ontario and McMaster Universities Osteoarthritis In- Pittsburgh Sleep Diary, S184 dex (WOMAC), S67 Pittsburgh Sleep Quality Index (PSQI), S184 Work Limitations Questionnaire (WLQ), S85 Primary Care Evaluation of Mental Disorders-Mood Module World Health Organization’s Quality of Life Instruments, $113 (PRIME-MD), S134 See also Assessment psychological well-being, S134, S165 Meclofenamate, dyspepsia and, meta-analysis, 508 Quality of Well-Being Scale (QWB), 23, S113 Medical costs Quebec Back Pain Disability Scale, S43 of arthritis, 101 RA, affective disorder in: receiver operator characteristic ana- health care utilization among older adults with arthritis, 164 lysis, 368 OA, socioeconomic impact of, in Hong Kong, 526 RA, Cedars-Sinai Health-Related Quality of Life Instrument, 78, RA, costs and cost predictors, in Spain, 64 798 Medical Outcomes Study (MOS) Sleep Scale, S184 RA, CES-D for assessing depression, 368, 549 Methotrexate (MTX) RA, Endler Multidimensional Anxiety Scales (EMAS), 368 PsA, efficacy of infliximab with MTX in resistant PsA, 541 RA, health-related quality of life patient questionnaires in clin- RA, hepatitis C and MTX, 843 ical practice, 574 RA, pneumonitis after initiation of therapy, 617 RA, measures for, S214 Microbes, in the joints, 479 RA, Positive and Negative Affect Schedule, 368 Microscopic polyangiitis (MPA) RA, quality of life related to social support and disease knowl- first signs of, 709 edge in women, 221 with poor prognosis factors, treatment with glucocorticoids and RA, self-report questionnaires in clinical practice, 59 cyclophosphamide pulses, 93 RA, validation of satisfaction questionnaire for multidisci- primary systemic vasculitides in Spain, epidemiology, 388 plinary care, 193 Mitral valve disease, with RA, 866 RA, Valspar 9 Whole Body Range of Motion Work Sample test, Moberg pickup test, 626 71 Mobility assessment, Tinetti Performance-Oriented Mobility As- RA, Work Instability Scale (WIS), 349 sessment (POMA), S28 Rapid Assessment of Disease Activity in Rheumatology (RA- Models DAR), S214 disability models, exercise and physical activity interventions RAQoL, S113 and, 114 Revised Leeds Disability Questionnaire, S197 joint disease models, loading and, 239 Rheumatoid Arthritis Disease Activity Index (RADAI), S214 Modified Health Assessment Questionnaire (MHAQ), S15 Rheumatoid Arthritis Pain Scale (RAPS), S96 Monarthritis, fatigue fractures suggesting, 741 Rheumatoid Arthritis Self-Efficacy Scale (RASE), S147 Mood, primary systemic vasculitis, quality of life and psycholog- Rheumatoid Arthritis Work Instability Scale (RA-WIS), S85 ical adjustment in, 826 Rheumatoid Hand Functional Disability Scale, S59 Morbidity, SLE, participatory patient-physician communication Roland-Morris Low Back Pain Measure, S43 and, 810 Rosenberg Self-Esteem Scale, S165 Multi-Dimensional Health Locus of Control Scale (MHLC), S147 Satisfaction with Life Scale (SWLS), S165 Multidimensional Assessment of Fatigue Scale, $175 Self-Administered Comorbidity Questionnaire (SCQ), 156 Multidisciplinary team care, RA, validation of satisfaction ques- self-efficacy, helplessness, mastery, and control, $147 tionnaire for, 193 Self-Efficacy Scale (SES), S147 Multiorgan dysfunction, ANCA in patients with, 151 Short Form-36 (Energy/Fatigue) Subscale of the Short Form Murine models, anti-TGF-f treatment and skin and lung fibrosis Health Survey, S113, $175 in sclerodermatous graft-versus-host disease, 611 Short-Form McGill Pain Questionnaire (SF-MPQ), S96 Muscle dysfunction, knee OA, rehabilitation and, 444 Shoulder Disability Questionnaire, S50 Muscle function, SS, physical capacity in, 681 Shoulder Pain and Disability Index (SPADI), S50 Muscle strength, recent-onset RA, strength training and physical Sickness Impact Profile (SIP), S113 function and working capacity, 71 Simple Shoulder Test, S50 Muscles SIP-RA, $113 colchicine myopathy in familial Mediterranean fever, 614 SLE, European Consensus Lupus Activity Measurement exercise and physical activity in children, benefits of, 435 knee OA, dysfunction and effective rehabilitation, 444 (ECLAM), 335 knee OA, isometric muscle force measurement, 29 SLE measures, S225 Musculoskeletal system sleep measures, S184 chronic upper extremity pain and co-occurring symptoms, 697 Stanford Health Assessment Questionnaire, validation of Japa- resultant and local loading in joint disease models, 239 nese version of, 784 Myalgia, with anticholesterolemic treatment, malignant hyper- State-Trait Anxiety Index (STAI), S165 thermia susceptibility and, 237 Systemic Lupus Activity Measure (SLAM), S225 Systemic Lupus Erythematosus Disease Activity Measure (SLE- DAI), $225 N Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index (SLICC/ACR-DI; NASS Lumbar Spine Outcome Assessment Instrument, S43 SDI), S225 National Arthritis Action Plan, implementation, 471 Timed Chair Stand Test, S28 Neck Disability Index, S43 Timed Up and Go Test, S28 Neck function, measures of, S43 Tinetti Performance-Oriented Mobility Assessment (POMA), Neovascularization, around optic nerve in GCA, 737 $28 Nitrate medications, OA, use of and new radiographic findings in Trust in Physician Scale with rheumatic disease patients, 51 hip OA in older women, 752 Valspar 9 Whole Body Range of Motion Work Sample test, Nonsteroidal antiinflammatory drugs (NSAIDs), meta-analysis of strength training in recent-onset RA, 71 dyspepsia and, 508 897 North American Spine Society (NASS) Lumbar Spine Outcome Assessment Instrument, S43 Nottingham Health Profile, S113 Pain Nucleolar phosphoprotein B23, autoantibodies against B23 in adult measures of, S96 SSc, associated with pulmonary hypertension, 85 AS measures, $197 Numbness, chronic upper extremity pain and co-occurring symp- chronic upper extremity pain and co-occurring symptoms, 697 toms, 697 FM, assessment, S210 FM, operant behavioral treatment, 314 in juvenile arthritis, 272 O measures of adult back and neck function, $43 measures of adult hand function, S59 Occupational risk, predicting onset of forearm pain, 519 measures of adult lower extremity function, S67 Older adults measures of adult quality of life, S113 arthritis, health care utilization and, 164 measures of adult shoulder function, S50 OA, cost effectiveness of COX-2 inhibitors, 283 measures of adult work disability, S85 OA, knee OA and vertebral and nonvertebral fractures, 648 pediatric measures of pain, S90 OA, nitrate medication use and new radiographic findings in pediatric measures of quality of life, S105 hip OA, 752 primary systemic vasculitis, quality of life, psychological ad- OA, quality of well-being in, 23, $113 justment and, 826 RA, cost effectiveness of COX-2 inhibitors, 283 RA measures, S96, S214 rehabilitation perspectives on compensatory mechanics in gait, SLE measures, $225 248 Pain Behavior Observation Method, S90 Oligoarthritis, family history of psoriasis and oligoarticular JIA, Pain Coping Questionnaire (PCQ), S90 488 Pan-bacterial polymerase chain reaction (PCR), OA or RA, bacte- Operant treatment, in FM, 314 rial components in synovial tissue, 328 Organ damage Parent’s Arthritis Self-Efficacy Scale (PASE), S147 juvenile-onset SLE, assessment of, 501 Patient education SLE, participatory patient-physician communication and, 810 hip dysfunction, outcome of “hip school,” 321 SSc, severe organ involvement in SSc with diffuse scleroderma, RA, group education for patients and partners, 556 606 RA, value of, 738 Orthopedic surgery, RA, declining use in, 216 Patient Generated Index (PGI), S113 Oslo-Truto-Amsterdam (OSTRA) Collaborative Study, RA, dam- Patient perceptions, of SSc, 689 age associated with low BMD and vertebral deformities, 209 Patient-physician communication, morbidity in SLE and, 810 Osteoarthritis (OA) Patient trust, use of Trust in Physician Scale, 51 bacterial components in, 328 Pediatric Orthopedic Surgeons of North America (POSNA) Pedi- costs of arthritis, 101 atric Musculoskeletal Functional Health Questionnaire, S5 COX-2 inhibitors, cost effectiveness of, 283 glucosamine therapy, current status, 601 Pediatric Pain Questionnaire (PPQ), S90 health-related quality of life measure in clinic population, 658 Pediatric Quality of Life (PedsQL), S105 hip, nitrate medication use and new radiographic findings in Pediatrics. See Children; Juvenile arthritis; Juvenile dermatomy- older women, 752 ositis; Juvenile idiopathic arthritis; Juvenile-onset systemic hip, sporting activity and development of, 228 lupus erythematosus; Juvenile rheumatoid arthritis hip dysfunction, outcome of “hip school,” 321 Perceptions, SSc, patients’ perceptions of, 689 knee, exercise effects on outcome, mechanical environment Performance-related measures, relationship between self-report and, 255 and, 535 knee, isometric muscle force measurement for, 29 Pharmacoeconomics, OA or RA, cost effectiveness of COX-2 in- knee, muscle dysfunction and effective rehabilitation, 444 hibitors, 283 knee, preoperative predictors of locomotor ability following Physical activity total knee arthroplasty, 36 Arthritis Foundation community-based programs, 463 knee, vertebral and nonvertebral fractures in the elderly, 648 children with arthritis, benefits of, 435 quality of well-being in older patients, 23 community-based physical activity intervention, 455, 463, 471 self-report and performance-related measures, relationship be- correlates of, 136 tween, 535 disability models, physical activity interventions and, 114 socioeconomic impact of, in Hong Kong, 526 National Arthritis Action Plan implementation, 471 Trust in Physician Scale, use, 51 physical activity levels in US population with and without walking aids, possession and use of, 838 arthritis, 129 Osteoporosis public health benefits of, 122 hip OA, nitrate medication use and new radiographic findings Work Group Recommendations: 2002 Exercise and Physical in older women, 752 Activity Conference (St. Louis), 121, 141, 261, 280, 453, 477 RA, OSTRA Study, 209 See also Exercise RA, vertebral deformities and BMD, 209, 355 Physical capacity, in SS, 681 update in, 732 Physical function Oswestry Low Back Pain Disability Index, S43 in AS, 483 Outcomes disability models, 114 complementary therapies and, 619 recent-onset RA, effect of strength training, 71 hip dysfunction, outcome of “hip school,” 321 Physical Performance Test (PPT), S28 HIV-associated PM, 172 Physician specialty, coxibs, use and discontinuation influenced OA, exercise effects on knee OA outcome, mechanical environ- by, 293 ment and, 255 Physicians OA, quality of well-being in older patients, 23 redesigning rheumatology practice, 716 RA, impact of socioeconomic status on course of, 567 SLE, participatory patient-physician communication and mor- RA, sE-selectin for stratifying outcome, 546 bidity, 810 SLE, participatory patient-physician communication and mor- Trust in Physician Scale, use of, 51 bidity in, 810 Piroxicam, dyspepsia and, meta-analysis, 508 SSc, fibrosing alveolitis in and outcome, 610 Pittsburgh Sleep Diary, S184 898

ebook img

Arthritis & Rheumatology 2003: Vol 49 Index PDF

13 Pages·2003·4.1 MB·English
by  
#periodicals #sim_microfilm #pub_arthritis-rheumatology
Save to my drive
Quick download
Download
Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview Arthritis & Rheumatology 2003: Vol 49 Index

AUTHOR INDEX Arthritis Care & Research, Volume 49, Numbers 1-6, 2003 A Brown L, 819 Dinant HJ, 567 Govoni M, 145 Bruet A, 93 Doran MF, 216 Grambow SC, 619 Abasolo L, 64 Brun JG, 187 Dorner T, 546 Gravallese EM, 149 Agard C, 709 Brunner HI, 335 Downs L, 394 Griffin K, 689 Albrecht A, 546 Buckley L, 732 Doyle J, 59 Groessl EJ, 23 Alderdice J, 617 Buratti S, 501 Duarte-Salazar C, 501 Gromnica-Ihle E, 314 Alexiades-Armenakas MR, Burckhardt CS, S96 Dueymes M, 804 Guerrero J, 388 494 Burmester GR, 546 Dunlop DD, 101, 121, 164 Guillevin L, 93, 633, 709, 819 Allaire SH, S85 Bush TM, 810 Dupond JL, 633 Guis S, 237 Allison J, 293 Bystryn JC, 494 Dyer A, 300 Gummesson C, 697 American College of Gwilliam PDH, 689 Rheumatology Ad Hoc E Gyurcsik NC, 306 Committee on Immunologic Cc Testing Guidelines, 399 Edmonds J, 29 Anaya JM, 738 Cadd WT, 16 Egerer K, 546 H Cadena J, 738 Anderson DL, 148 Eisen SA, 745 Callahan LF, 51, 658, 724 Hagen LE, 3 Anderson LA, 51 Ekdahl C, 681, 697 Cantini F, 541 Hakkinen A, 71, 789 Anderson RJ, 421 Elder ME, 862 Carmona L, 64 Hakkinen K, 789 Andre MH, 633 El-Hajj I, 737 Carr A, $113 Halse Jl, 355 Ansart S, 804 Emery HM, 862 Catanoso MG, 541 Hamidou H, 93 Anthony KK, 272 Escalante A, 200 Cavazzini L, 145 Ham SA, 129 Appelboom T, 142 Estabrooks PA, 306 Chamberlain MA, 349 Handwerger BS, 16 Aréne JP, 93 Ettinger WH, 453 Chan A, 526 Hannonen P, 71, 789 Ariza-Ariza R, 483 Evidence-Based Medicine Chan C, 526 Hanson KD, 766 Arlaud J, 633 Working Groups in Chang RW, 101, 164, 280 Hara M, 784 Armesto V, 737, 741 Rheumatology, 377, 574 Chan KM, 526 Harms-Ringdahl K, 321 Arroliga AC, 151 Eyler AA, 136, 141 Chen T, 328 Harrington JT, 716 Arroyo RA, 200 Chiou CF, 78, 798 Harrison MJ, 846 Association of Rheumatology Chiu P, 526 F Harrold E, 826 Health Professionals Christoforov B, 633 Harth M, 144 Outcomes Measures Task Falch JA, 355 Chuzhin Y, 617 Harvey A, 349 Force, S15 Fang MA, 745 Atroshi I, 697 Cid MC, 819 Farraye FA, 614 Hashimoto H, 594, 867 Cipriani J, 640 Haugeberg G, 209, 355 Feist E, 546 Clark A, 239 Hayes KW, S28 B Feldman BM, 3, 335 Clark DO, 179 Fifield J, 368, 740 Hazes JMW, 193, 665 Badamgarav E, 377 Clements M, 843 Figarella-Branger D, 237 Heijmans M, 838 Baldassano M, 494 Cohen P, 93 Finch W, 745 Hellmann DB, 819 Bartlett SJ, 778 Corbo JC, 614 Fischbach M, 200 Helmick CG, 129 Bathon JM, 778 Cordier JF, 93 Fitzgerald O, 221 Hernandez-Garcia B, 483 Battafarano DF, 200 Courtney PA, 617 Flores RH, 16 Hernandez-Garcia C, 64 Baty V, 633 Cozzone PJ, 237 Flor H, 314 Hernandez-Rodriguez J, 819 Beach S, 640 Criscione LG, 361 Fortune DG, 689 Herrero-Beites A, 736 Bellajdel B, 64 Croft JD Jr., 377, 574 Fossel AH, 156 Herrick AL, 689 Bendahan D, 237 Cronan TA, 23 Fox A, 640 Hertzer J, 546 Berger ML, 508 Crosbie J, 29 Fox PC, 585 Herzog W, 239, 261 Bergink AP, 648 Crowson CS, 216 Frahm-Templar MJ, 306 Hesselbrock V, 368, 740 Beristain-Manterola R, 501 Cummings SR, 752 Franks AG Jr., 494 Hewett JE, 549, 766 Bernard V, 237 Cummins MJ, 585 Fransen J, S214 Hewlett S, 281 Bernsen RMD, 228 Cunningham F, 745 Fransen M, 29 Hjortdahl P, 342 Bernstein B, 501 Currey SS, 51, 658 Freburger JK, 51 Hochberg MC, 752 Bierma-Zeinstra SMA, 228 French Vasculitis Study Hoffman GS, 151, 819 Bilderback A, 778 D Group, 93 Hofman A, 648 Bince B, 494 Furst DE, 574 Hohlbauch A, 377, 574 Blanche P, 633 Damush TM, 179 Hgiseth A, 355 Bode RK, 7 D’Arbonneau F, 804 G Holm MB, 640 Boiardi L, 541 Da Silva E, 216 Hootman JM, 122, 129, 141 Boissonnas A, 633 DeFriese GH, 724 Gabriel SE, 703 Hunder GG, 149, 703 Bombardier C, 335 Degotardi P, S105 Garcia-Porrua C, 388, 737, Hung YY, 752 Boonman DCG, 665 de Jong Z, 665 741, 866 Hunt IM, 519 Borenstein J, 78, 798 Dekker J, 838 Gelber AC, 85 Hurley MV, 444, 453 Boshuizen HC, 567 Dellaripa PF, 819 Gelfand SG, 144, 618 Boutaugh ML, 463, 477 Del Rincén I, 200 Gerloni V, 501 I Bowyer S, 300 Desvaux A, 633 Giasi V, 147 Bozzola E, 488 Detournay B, 633 Gilson B, 93 Inaba Y, 594, 867 Brady TJ, 471, 477, S147 DeVellis BM, 724 Gilworth G, 349 Inman RD, 479 Brandt KD, 267, 280 DeVellis RF, 724 Gollish JD, 535 Irrgang JJ, S67 Breedveld FC, 193 Dhote R, 633 Gonzalez-Gay MA, 388, 737, Irvin WS, 766 Brekke M, 342 Dijkmans BAC, 209 741, 866 Isenberg DA, S225 Bresnihan B, 221 Dimachkie MM, 172 Gonzalez-Juanatey C, 866 Iversen MD, S210 Lechman TS, 7 Munneke M, 665 Lee P, 526 Murphy FT, 200 Jacobi CE, 567 Lefevre P, 722 Mutran EJ, 724 Qi R, 179 Jacobsson LTH, 681 Lems WF, 209 Jalava J, 328 Liang MH, 156, 574, 720 R Jamison M, 673 Lidov HGW, 421 N Jansen A, 665 Lietsalmi AM, 71 Ramsey-Goldman R, 300, Jenckes MW, 819 Lievense AM, 228 Naglie G, 283 $225 Jette AM, 114, 121 Lilleadse F, 355 Nahit ES, 519 Rao JK, 179, 619, 658 Johnson GE, 766 Lipton R, 300 Nakajima N, 594 Rapoff MA, S90 Johnson ME, S28 Llorca J, 388 Nakayama T, 594 Rasker JJ, 556 Johnson RW, 172 Lodder MC, 209 Navarro-Sarabia F, 483 Ravelli A, 488, 501 Johnsson R, 697 Lo Scocco G, 541 Neuberger GB, 673, S175 Reiff A, 501 Johnston SK, 766 Lotstein D, 810 Neuwelt CM, 810 Reisine S, 368, 740 Jones KD, S96 Louie JS, 377 Nevitt MC, 752 Reveille JD, 172, 399 Jonsson R, 187 Loukes J, 689 NIAMS Juvenile DM Registry Richards HL, 689 Jordan JM, 724 Lubeck DP, 78, 798 Physician Referral Group, Riemsma RP, 556 Jover JA, 64 Lu TT, 862 300 Rimpildinen M, 328 Juarez L, 293 Luukkainen R, 328 Niccoli L, 541 Ritter J, 617 Nielson W, 144 Roberts WN, 843 Lyyski T, 789 K Niles JL, 151 Rodriguez-Ledo P, 388 Nuenninghoff DM, 858 Roettcher P, 300 Kalappa N, 16 M Numano F, 594 Rogers JC, 640, S67 Kamatani N, 784 Nyman K, 789 Ronday HK, 665 Kamino H, 494 Macchioni P, 541 Rosen A, 85 Kammer GM, 585 Macera CA, 122, 129, 141 Rosenstein ED, 617 Kaplan RM, 23 Macfarlane GJ, 519 O Roth EA, 508 Katz JN, 156, S43 Machold KP, 626 O'Dell J, 377 Rothfield N, 368, 740 Katz P, 377 Maclean CH, 508 O’Fallon WM, 216, 703 Roubenoff R, 263, 280 Katz PP, S1, S15 Madland TM, 187 Ofman JJ, 78, 377, 508, 574, Roudier J, 722 Kaufman L, 617 Maeno N, 501 798 Rubin HR, 819 Kautiainen H, 71 Maetzel A, 283 Ohno Y, 594, 867 Rudolph PE, 546 Kawamura T, 594, 867 Magni-Manzoni S, 488 Olivieri I, 147, 541 Ruggieri AP, 853 Kazi S, 172 Mahr A, 93, 709 Olivieri J, 293 Ruivard M, 93 Kennedy D, 535 Maldonado-Velazquez MR, Orces C, 703 Ruperto N, 488, 5014 Keyser RE, 16 501 Ornstein E, 697 Rupp I, 567 Keysor JJ, 114, 724 Manana P, 741 @rstavik RE, 209, 355 Russak SM, 78, 574, 798 Kim LH, 605 Manheim LM, 101, 164 Ostbye T, 144 Russell A, 142 Kissin EY, 614 Mann JA, 599 Rus V, 16 Klassbo M, 321 Manthorpe R, 681 Klein-Gitelman MS, 7 Martens MP, 549 P Klepper SE, 435, 453, S5 Martini A, 488, 501 Kobayashi S, 594, 867 Matsuda Y, 784 Pacheco-Tena C, 479 Saag KG, 293 Koes BW, 228 Matsumoto AK, 778 Pachman LM, 7, 300 Sailler L, 633 Komatireddy GR, 766 Matsumoto Y, 594, 867 Padula A, 147, 541 Saito T, 784 Konrad TR, 724 Mattei JP, 237 Pagura SMC, 535 Salisbury D, 745 Kooiman KG, 193 Matteson EL, 216, 858 Papas A, 585 Salvarani C, 541 Korn JH, 605 Maver J, 280 Papo T, 633 Sandborg CI, 759 Kostense PJ, 209 Mayer ML, 759 Parent E, 36 Sanders L, 361 Koutantji M, 826 McClure P, S50 Parker JC, 549, 766 Sangha O, 156 Kovac SH, 293 McGibbon CA, 248, 261 Patino FG, 293 Saulsbury FT, 599 Kozak-Ribbens G, 237 McQuillan J, 368, 740 Paulus HD, 78, 574, 798 Scarano E, 147 Krahn M, 283 Mechenstock D, 633 Pearce S, 826 Scarborough DM, 248 Kramer N, 617 Meenan R, 477 Pego-Reigosa R, 737 Schaeffer A, 633 Krebs DE, 248, 261 Mellins ED, 759 Pellissier JF, 237 Schanberg LE, 272, 280 Kroenke K, 619 Mendez EP, 300 Pennec YL, 804 Schiaffino KM, S165 Kujawska A, 843 Merkel PA, 151, 614, 819 Perez-Ruiz F, 736 Schneider R, 3 Kvien TK, 209, 342, 355 Michener L, S50 Perkins SM, 179 Schulz R, 640 Kwok T, 526 Mihaliak KA, 619 Person S, 293 Schumacher HR Jr., 413 Mikuls TR, 293 Pertuiset E, 93 Schuster SJ, 394 L Miller ML, 7 Peter WFH, 665 Schwab P, 421 Miller P, 673 Piedmont R, 778 Schwartz RB, 421 Labussiere AS, 633 Minnock P, 221 Piette AM, 633 Scott DGI, 826 Lajas C, 64 Minor MA, 1, 428, 453 Piette JC, 633 Sengupta N, 78, 798 Lam D, 526 Moadel AB, 78, 798 Pincus T, 59 Sharma L, 255, 261 Lando A, 237 Modrusan D, 3 Pisetsky DS, 149, 361 Sharpe PA, 455, 477 Lane NE, 752 Moffet H, 36 Pistorio A, 488, 501 Sheehan TJ, 368, 740 Lane SE, 826 Mol GD, 567 Ploner A, 626 Shekelle PG, 508 Lanoux P, 93 Moncur C, S197 Pols HAP, 648 Shepherd R, 745 Larroche C, 633 Moreland L, 293, 574, 819 Poole JL, S59 Sherbourne CD, 78, 798 Larsson G, 321 Morton SC, 508 Poullin P, 722 Silman AJ, 519 Lau CS, 526 Mottonen T, 328 Pratsidou-Gertsi P, 501 Silverman ED, 335 Lau E, 526 Mouthon L, 93, 709 Priesmeyer ML, 766 Simkin PA, 735 Lazaro P, 64 Mudano A, 293 Proven A, 703 Simon J, 633 Le Berre R, 804 Mugnier B, 722 Puéchal X, 93 Simon LS, 574 890 Singh G, 784 Sundaramurthy S, 810 Ulanet DB, 85 Weinstein B, 394 Singh JA, 745 Urano W, 784 Weisman MH, 78, 574, 798 Siva C, 745 T Uthman I, 737 Werth V, 494 Slaughter JR, 549, 766 Whitehead EM, 617 Smarr KL, 549, 766, S134 Taal E, 556 V White KP, 144 Smith J, 349 Taher A, 737 White P, 377 Smith MT, S184 Takei S, 501 Vainio O, 328 Wigley FM, 85 Smolen J, 626 Tamakoshi A, 594, 867 van den Bos GAM, 567 Williams EN, 752 Smyth MG, 349 Tanaka E, 784 van den Ende CHM, 665 Williams FM, 172 Sniezek JE, 122, 129, 141, 471 Taniguchi A, 784 Van Der Esch M, 838 Winfield JB, 658 Sokka T, 71 Taylor S, 519 van der Klift M, 648 Wise CM, 843 Solomon DH, 399 Tennant A, 349 Vanhille P, 93 Wolfe F, 59 Somer BG, 394 Tennen H, 368, 740 van Leeuwen JPTM, 648 Woodhouse A, 349 Song J, 101, 164 Testa A, 866 van Riel PLCM, S214 Woo J, 526 Soter NA, 494 Thieme K, 314 Vargas E, 64 Woolf AD, 209 Speechley M, 144 Thompson AK, 59 Vassilopoulos D, 151 Wu J, 239 Spencer CH, 501 Tierney WM, 179 Verhaar JAN, 228, 648 Spiera R, 819 Tijhuis GJ, 193 Verhagen AP, 228 Y Stamm TA, 626 Toivanen P, 328 Villa-Forte A, 151 Yamanaka H, 784 Starz TW, 640 Tomatsu T, 784 Viola S, 488 Yano T, 594, 867 St.Clair EW, 361 Towheed TE, 601 Vliet Vlieland TPM, 193, 665 Yasuda K, 594 Stenstr6m CH, 428, 453 Traboulsi R, 737 Von Scheven E, 862 Yelin EH, 101, 121 Stephens D, 3 Treffouret S, 237 Yli-Jama T, 328 Stern R, 745 Trotta F, 145 Ww Youinou P, 804 Stone JH, 819 Tsai DE, 394 Yutani C, 594 Stratford PW, 535 Tsitsami E, 488 Walker SE, 549, 766 Straus WL, 508 Tugwell P, 574 Wara DW, 862 Z Street RL Jr., 810 Ward MM, 810 Strombeck B, 681 U Warrington KJ, 858 Zarabadi SA, 745 Stucki G, 156, S214 Watts RA, 826 Zhang J, 526 Suarez-Almazor ME, 377 Uhlfelder ML, 819 Weaver A, 377 Zhang X, 479 Sugarman J, 361 UhlT,i 209g, 3 55 Wegener ST, $184 Ziza JM, 633 Sullivan EJ, 151 Jitterlinden AG, 648 Weinberger M, 179, 619 Zwinderman AH, 193, 665 SUBJECT INDEX Arthritis Care & Research, Volume 49, Numbers 1—6, 2003 A Arthritis (cont’d) physical activity levels in US population with and without Access to care, pediatric rheumatology care in US, access to, 759 arthritis, 129 Activities of daily living (ADL) rehabilitation perspectives on compensatory mechanics in gait, disability assessment using performance in the home, concor- 248 dance of methods, 640 self-management strategy use, 724 RA, falls and fear of falling and, 673 See also Rheumatoid diseases; specific types of arthritis Activities of Daily Living Scale of the Knee Outcome Survey Arthritis Foundation, community-based physical activity pro- (ADLS), S67 grams, 463 Acute low back pain (ALBP), self-management program for, 179 Arthritis Hand Function Test (AHFT), S59 Adherence. See Treatment adherence Arthritis Helplessness Index (AHI)/Rheumatology Attitudes In- Adverse events, dyspepsia and NSAIDs, meta-analysis, 508 dex (RAI), S147 Aerobic capacity Arthritis Impact Measurement Scales (AIMS/AIMS2), S113 exercise and physical activity in children, benefits of, 435 Arthritis Self-Efficacy Scale (ASES), S147 SS, physical capacity in, 681 Arthroplasty, preoperative predictors of locomotor ability follow- Aerobic exercise, RA, benefits of, 428 ing total knee arthroplasty, 36 Aerobic insufficiency, SLE, women with, 16 Aspiration, for joints, 413 Affect Balance Scale (ABS), S165 Assessment Affective disorder, RA, receiver operator characteristic analysis, of adult back and neck function, S43 368 of adult general functional status, $15 African American population, RA, ethnic variation in clinical of adult general performance tests, S28 manifestations, HLA-DRB1 alleles and, 200 of adult hand function, S59 Alternative medicine. See Complementary and alternative medi- of adult lower extremity function, S67 cine of adult measures of pain, S96 American Academy of Orthopedic Surgeons Lower Limb Ques- of adult quality of life, S113 tionnaire, S67 of adult shoulder function, S50 American College of Rheumatology (ACR), new policy on disclo- of adult work disability, S85 sure of interest for journals, 149 AS measures, S197 American Shoulder and Elbow Surgeons Standardized Shoulder of depression and depressive symptoms, 368, 549, S134 Form, S50 of disability, using performance in the home, 640 Amyloid deposits, cerebral amyloid angiopathy associated with of fatigue, S113, $175 primary angiitis of the nervous system, 2 case reports, 421 FM measures, $210 Aneurysm, concomitant giant cell aortitis, thoracic aortic aneu- innovation in capturing data about functional status, 853 rysm, and aortic arch syndrome, 858 juvenile-onset SLE, organ damage in, 501 Ankylosing spondylitis (AS) OA, content validity of timed tests, 535 measures of, 483, S197 pediatric function, S5 physical function and health-related quality of life in, 483, $197 pediatric measures of pain, S90 Ankylosing Spondylitis Quality of Life (ASQOL), S197 pediatric measures of quality of life, S105 Anti-Scl-70 autoantibodies, SSc, guidelines for immunologic test- of psychological well-being, S134, S147, S165 ing, 399 Quality of Well-Being Scale, 23, $113 Anti-transforming growth factor f (anti-TGF-£), treatment for skin RA, depression in, 549 and lung fibrosis in murine sclerodermatous graft-versus-host RA, health-related quality of life patient questionnaires in clin- disease, 611 ical practice, 574 Anticentromere autoantibodies, SSc, guidelines for immunologic RA, quality of life related to social support and disease knowl- testing, 399 edge in women, 221 Anticholesterolemic treatment, rhabdomyolysis and myalgia RA, self-report questionnaires in clinical practice, 59 with, malignant hyperthermia susceptibility and, 237 RA measures, S96, S214 Antidepressants, depression in RA, combined pharmacologic and of self-efficacy, helplessness, mastery, and control, S147 cognitive-behavioral approach, 766 SLE measures, S225 Antineutrophil cytoplasmic antibodies (ANCA), in diseases that sleep measures, S184 mimic systemic vasculitides, 151 See also Measuring instruments Antinucleolar antibodies (ANA), SSc, guidelines for immunologic Assistive devices, RA and OA, walking aids, possession and use testing, 399 of, 838 Anxiety Atorvastatin, rhabdomyolysis and myalgia with, malignant hyper- measures of psychological well-being, S134, S165 thermia susceptibility and, 237 RA, receiver operator characteristic analysis of affective disor- Autoantibodies, against B23 in SSc, associated with pulmonary der in, 368 hypertension, 85 Aortic aneurysm, concomitant giant cell aortitis, thoracic aortic B aneurysm, and aortic arch syndrome, 858 Aquatic exercise, in arthritis, 306 B23, autoantibodies associated with pulmonary hypertension, 85 Arthritis Back function, measures of, S43 aquatic exercise in, 306 Back pain consent to research: quantity of information versus quality, 281 acute low back pain (ALBP), self-management program for, 179 correlates of physical activity, 136 measures of, S43 cost of, 101 Bacteria, in RA or OA, 328 exercise and physical activity in children, benefits of, 435 Balance, Berg Balance Scale, S28 health care utilization among older adults with, 164 Barthel Index, S15 inflammatory disease and exercise, 263 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Moberg pickup test, 626 S197 892 Bath Ankylosing Spondylitis Functional Index (BASFT) Comorbidity overview, S197 coxibs, use and discontinuation influenced by, 293 reliability of Spanish version of, 483 Self-Administered Comorbidity Questionnaire (SCQ), 156 Bath Ankylosing Spondylitis Global Score (BAS-G), S197 Complementary and alternative medicine Bath Ankylosing Spondylitis Metrology Index (BASMI), S197 for pediatric patients, 3 Beck Depression Inventory (BDI), $134 use by rheumatology patients: one-year study, 619 Behavior therapy, FM, operant behavioral treatment, 314 Control, measures of, S147 Behavioral Risk Factor Surveillance System (BRFSS), health-re- Costs. See Medical costs; Pharmacoeconomics lated quality of life measure, 658 Cyclooxygenase 2 (COX-2) inhibitors Behcget’s disease, infliximab treatment for child, 599 cost effectiveness of rofecoxib and celecoxib in OA or RA, 283 Berg Balance Scale, S28 use and discontinuation of, physician specialty and patient Bible, did Moses inherit SpA, 142 comorbidities and, 293 Biopsy, SS, risk factors for positive minor salivary gland biopsy Cyclophosphamide, for polyarteritis nodosa and microscopic findings in, 145 polyangiitis with poor prognosis, 93 Bone mineral density (BMD) hip OA, nitrate medication use and new radiographic findings in older women, 752 D RA, damage associated with low BMD and vertebral deformi- Data collection, innovation in capturing data about functional ties, OSTRA Study, 209 status, 853 RA, vertebral deformities in women and, 355 Day patient care, RA, validation of satisfaction questionnaire for, Bosentan therapy, SSc, pulmonary arterial hypertension in, 608 193 British Isies Lupus Assessment Group (BILAG), S225 Depression Button test, comparison of Moberg pickup test with, 626 measures of, 368, 549, S134 RA, assessment of in, 549 Cc RA, combined pharmacologic and cognitive-behavioral ap- proach, 766 Caregivers, RA, quality of life related to social support and disease RA, receiver operator characteristic analysis of affective disor- knowledge in women, 221 der in, 368 Cedars-Sinai Health-Related Quality of Life Instrument Dermatomyositis (DM) development of, 78 Disease Activity Score for juvenile DM, 7 validation of, 798 US incidence of juvenile DM: 1995-1998, 300 Celecoxib, cost effectiveness in OA or RA, 283 Disabilities of the Arm, Shoulder, and Hand (DASH), S50 Center for Epidemiological Studies Depression Scale (CES-D) Disability as measuring instrument, S134 AS, measures of, S197 RA, affective disorder in: receiver operator characteristic ana- assessment of using performance in the home, 640 lysis, 368 chronic upper extremity pain and co-occurring symptoms, 697 RA, depression in, 549 disability models, 114 Cerebral amyloid angiopathy, associated with CNS primary angi- FM, assessment of, S210 itis, 2 case reports, 421 measures of adult back and neck function, S43 CES-D, 368, 549, S134 measures of adult hand function, S59 Chapel Hill Consensus Conference definitions, primary systemic measures of adult lower extremity function, S67 vasculitides in Spain, epidemiology, 388 measures of adult quality of life, S113 Child Health Assessment Questionnaire (CHAQ), S5 measures of adult shoulder function, S50 Children measures of adult work disability, S85 access to pediatric rheumatology care in US, 759 measures of depression and depressive symptoms, S134 Behcet’s disease, infliximab treatment, 599 measures of pain, S96 complementary and alternative medicine used by, 3 measures of psychological well-being, S134, S147, S165 exercise and physical activity in children with arthritis, benefits pediatric measures of pain, S90 of, 435 pediatric measures of quality of life, S105 measures of pediatric function, S5 RA, measures of, S96, S214 measures of pain, S90 RA, strength training and disability in recent-onset RA, 71 measures of quality of life, S105 RA, Work Instability Scale, 349 measures of self-efficacy, helplessness, mastery, and control, RA and OA, possession and use of walking aids in, 838 S147 SLE, measures of, $225 pain in juvenile arthritis, 272, S90 Disease activity SLE, validation of ECLAM for, 335 childhood-onset SLE, validation of ECLAM and, 335 WG, risk of thrombosis, 862 juvenile DM, validity of Disease Activity Score, 7 Children’s Arthritis Self-Efficacy Scale (CASE), S147 primary systemic vasculitis, quality of life, psychological ad- Clinical Nurse Specialist, RA, validation of satisfaction question- justment and, 826 naire for, 193 Disease Activity Score (DAS) Clinical practice, RA, health-related quality of life patient ques- overview, S214 tionnaires used in, 574 validity for children with juvenile DM, 7 Clinical trials, informed consent process for RA treatment, 361 Disease course, RA, impact of socioeconomic status on course of, Cognitive-behavioral therapy, depression in RA, pharmacologic 567 approach combined with, 766 Disease knowledge, RA, quality of life related to, 221 Colchicine, myopathy in patient with familiar Mediterranean fe- Disease management programs, RA, functional status and, 377 ver, 614 Disease-modifying antirheumatic drugs (DMARDs), leflunomide Combination therapy, leflunomide for RA, safety of use, 745 for RA, safety of use, 745 Communication, SLE, participatory patient-physician communi- Disease Repercussions Profile (DRP), S113 cation and morbidity, 810 Dougados Functional Index (DF), $197 Community-based intervention Dry mouth. See Sicca symptoms Arthritis Foundation programs, 463 Dynamic exercise, RA, adherence with long-term intensive exer- National Arthritis Action Plan implementation, 471 cise (RAPIT Program), 665 physical activity intervention, 455, 463 Dynamic Gait Index (DGI), S28 Dyspepsia, NSAIDs and, meta-analysis, 508 Fibromyalgia (FM) (cont’d) operant behavioral treatment, 314 Trust in Physician Scale, use, 51 E Fibromyalgia Impact Questionnaire (FIQ), S210 Education. See Patient education Fibrosing alveolitis, SSc, outcome relationship to, 610 Elderly. See Older adults Fibrosis, SSc, anti-TGF-8 treatment in murine sclerodermatous Emotional distress, RA, receiver operator characteristic analysis graft-versus-host disease, 611 of affective disorder in, 368 Foot Function Index (FFI), S67 Endler Multidimensional Anxiety Scales (EMAS), RA, affective Forearm, predicting onset of pain in, 519 disorder in: receiver operator characteristic analysis, 368 Fractures Endurance training, RA, strength and endurance training (concur- fatigue fractures suggesting monarthritis, 741 rent) in, 789 hip OA, nitrate medication use and new radiographic findings Epidemiology in hip OA in older women, 752 forearm pain, predicting onset, 519 knee OA, vertebral and nonvertebral fractures in the elderly, GCA in Japan, 594 648 juvenile DM, US incidence 1995-1998, 300 osteoporosis update, 732 primary systemic vasculitides in Spain, 388 Functional assessment Errata, 148, 477, 740 AS measures, 483, S197 Ethics back and neck function, measures of, S43 informed consent process for clinical trial, 361 depression and depressive symptoms, measures of, 5134 new disclosure of interest policy for ACR journals, 149 disability assessment using performance in the home, 640 Ethnicity, RA, role of HLA-DRB1 alleles in clinical manifestations fatigue, measures of, S113, $175 of, 200 FM measures, S210 European Consensus Lupus Activity Measurement (ECLAM) general functional status, measures of, S15 childhood-onset SLE, validation in, 335 general performance tests, S28 overview, S225 hand function, measures of, S59 EuroQoL, $113 innovation in capturing data about functional status, 853 Exercise lower extremity function, measures of, S67 2002 Exercise and Physical Activity Conference, 1 Moberg pickup test, 626 aquatic exercise in arthritis, 306 pain, measures of, 590, S96 children with arthritis, benefits of, 435 pediatric function, measures of, S5 community-based intervention, Arthritis Foundation programs, pediatric measures of pain, S90 463 pediatric measures of quality of life, S105 community-based intervention, National Arthritis Action Plan psychological well-being, measures of, S134, S165 implementation, 471 RA measures, S96, S214 community-based physical activity intervention, 455, 463 quality of life, measures of, S105, S113 correlates of physical activity, 136 self-efficacy, helplessness, mastery, and control, measures of, disability models, implications for, 114 $147 inflammatory disease and, 263 SLE measures, S225 OA, exercise effects on knee OA outcome, mechanical environ- sleep measures, S184 ment and, 255 shoulder function, measures of, S50 OA, sporting activity and development of hip OA, 228 work disability, measures of, S85 physical activity levels in US population with and without See also Measuring instruments arthritis, 129 Functional Assessment System (FAS), S67 public health benefits of physical activity, 122 Functional outcome RA, adherence with long-term intensive exercise (RAPIT Pro- acute low back pain, self-management program, 179 gram), 665 OA, self-report and performance-related measures, relationship RA, benefit of aerobic and strengthening exercise, 428 between, 535 RA, strength and endurance training (concurrent) in, 789 Functional status, RA, disease management programs and, 377 SLE, aerobic insufficiency in women, 16 Work Group Recommendations: 2002 Exercise and Physical G Activity Conference (St. Louis), 121, 141, 261, 280, 453, 477 See also Physical activity Gait Exercise and Physical Activity Conference (St. Louis, 2002), Work assessment of, S28 Group Recommendations, 121, 141, 261, 280, 453, 477 locomotor ability following total knee arthroplasty, preopera- tive predictors, 36 F rehabilitation perspectives on compensatory mechanics in, 248 Gait Velocity test, S28 Falls, RA, falls and fear of falling and life activities, 673 Gas chromatography-mass spectrometry, OA or RA, bacterial Familial Mediterranean fever, colchicine myopathy in, 614 components in synovial tissue, 328 Families, RA, group education for patients and partners, 556 General Health Questionnaire (GHQ-12), S165 Family history, of psoriasis in oligoarticular JIA, 488 Generalized Self-Efficacy Scale (GSES), S147 Fatigue Generic health status, in rheumatic disease, 658 measures of, $113, $175 Genetics SLE, aerobic insufficiency in women, 16 RA, ethnic variation in clinical manifestations, HLA-DRB1 al- SS, physical capacity in, 681 leles and, 200 Fatigue fractures, suggesting monarthritis, 741 WG, risk of thrombosis and, 862 Fatigue Questionnaire, $175 Geriatric Depression Scale (GDS), S134 Fatigue Scale, S175 Giant cell arteritis (GCA) Fibromyalgia (FM) concomitant giant cell aortitis, thoracic aortic aneurysm, and generic health-related quality of life measure in clinic popula- aortic arch syndrome, 858 tion, 658 glucocorticoid therapy, 703 labeling: pros and cons, 144, 618 in Japan, clinical and epidemiologic analysis, 594 measure of, S210 neovascularization around the optic nerve in, 737 894 Giant cell arteritis (GCA) (cont’d) Immunohistochemical analysis, tumid LE, 494 quality of life aspects important to GCA patients, 819 Immunologic testing, SSc, guidelines for use of anticentromere, Glucocorticoids Scl-70, and nucleolar antibody testing, 399 for GCA, duration and adverse outcomes, 703 Index of Severity for Hip Osteoarthritis (ISH), S67 for polyarteritis nodosa and microscopic polyangiitis with poor Index of Severity for Knee Osteoarthritis (ISK), S67 prognosis, 93 Indomethacin, dyspepsia and, meta-analysis, 508 Glucosamine, for OA, current status, 601 Infectious agents Gouty arthritis, uric acid excretion, 735 in the joints, 479 Graft-versus-host disease, murine sclerodermatous graft-versus- OA or RA, bacterial components in, 328 host disease, anti-TGF-6 treatment of skin and lung fibrosis as Inflammatory disease, exercise, 263 model for human SSc, 611 Infliximab Grip Ability Test (GAT), S59 Behget’s disease, pediatric patient, 599 RA, MTX pneumonitis after initiation of therapy, 617 resistant PsA, efficacy in, 541 Informed consent, consent process for clinical trial, 361 Hand function Injection therapies, for joints, 413 measures of, S59 Insomnia Severity Index, S184 Moberg pickup test, 626 Instrumental activities of daily living (IADL), disability assess- Harris Hip Score (HHS), S67 ment using performance in the home, 640 Health Assessment Questionnaire (HAQ), S15, 784 Interferon (IFN) alfa, SS, oromucosal administration of, 585 Health Assessment Questionnaire for the Spondylarthropathies Interstitial lung disease, SSc, fibrosing alveolitis in and outcome, (HAQ-S), S197 610 Health care redesign, rheumatology practice, redesigning, 716 Intraarticular therapies, aspiration and injection therapies, 413 Health care utilization Isometric muscle force, knee OA, 29 older adults with arthritis, 164 RA, impact of socioeconomic status on disease course and use J of health care services, 567 Health status, RA, changes over 5 years, 342 Japanese populations, Stanford Health Assessment Question- Health-status questionnaires naire, validation of Japanese version, 784 RA, Cedars-Sinai Health-Related Quality of Life Instrument, 78, Jebsen Test of Hand Function, S59 798 Joint disease models, resultant and local loading in, 239 RA, health-related quality of life questionnaires, use in clinical Joint mobility, SS, physical capacity in, 681 practice, 574 Joint replacement RA, self-report questionnaires in clinical practice, 59 OA, preoperative predictors of locomotor ability following total Self-Administered Comorbidity Questionnaire (SCQ), 156 knee arthroplasty, 36 Helplessness, measures of, S147 OA, socioeconomic impact of in Hong Kong, 526 Hemophagocytosis, reactive hemophagocytic syndrome in sys- RA, declining use in, 216 temic disease, 633 Joint structures, response to immobilization and remobilization, Hepatitis B, severe RA with chronic hepatitis B, clinical improve- 267 ment with protein A immunoadsorption, 722 Joint surgery, RA, declining use in, 216 Hepatitis C, MTX and, 843 Joints Hip aspiration and injection therapies for, 413 Harris Hip Score (HHS), S67 joint structures, response to immobilization and remobilization, hip dysfunction, outcome of “hip school,” 321 267 Index of Severity for Hip Osteoarthritis (ISH), S67 Juvenile arthritis OA, nitrate medication use and new radiographic findings in measures of pain, S90 hip OA in older women, 752 measures of pediatric function, S5 OA, sporting activity and development of, 228 measures of quality of life, S105 Hispanic population, RA, ethnic variation in clinical manifesta- pain in children, 272, S90 tions, HLA-DRB1 alleles and, 200 Juvenile Arthritis Functional Assessment Report (JAFAR), S5 HLA-DRB1 alleles, RA, ethnic variation in clinical manifestations Juvenile Arthritis Functional Assessment Scale (JAFAS), S5 of, 200 Juvenile Arthritis Functional Status Index (JASI), S5 Hodgkin’s lymphoma, presenting as Tietze’s syndrome, 737 Juvenile Arthritis Quality of Life Questionnaire (JAQQ), S105 Hong Kong, socioeconomic impact of OA, 526 Juvenile dermatomyositis (DM) Hospital Anxiety and Depression Scale (HADS), 5134 Disease Activity Score for children, 7 Human immunodeficiency virus (HIV), HIV-associated PM, 172 US incidence 1995-1998, 300 Juvenile idiopathic arthritis (JIA), family history of psoriasis in oligoarticular JIA, 488 i Juvenile-onset systemic lupus erythematosus (SLE), organ damage Illness beliefs, SSc, patients’ perceptions of, 689 in, assessment, 501 Imaging Juvenile rheumatoid arthritis (JRA), pain in children with, 272 cerebral amyloid angiopathy associated with CNS primary an- giitis, 421 K enthesitis of SpA masquerading as Osgood-Schlatter disease, 147 Katz Index of Activities of Daily Living, S15 familial Mediterranean fever, colchicine myopathy in, 614 Kidneys OA, nitrate medication use and new radiographic findings in SSc, long-term outcomes of renal crisis, 607 hip OA in older women, 752 SSc, renal functional reserve impairment without clinical signs RA, damage associated with low BMD and vertebral deformi- of kidney involvement, 605 ties, OSTRA Study, 209 SSc, severe organ involvement in SSc with diffuse scleroderma, tumid LE, immunohistochemical classification criteria, 494 606 Immobilization, joint structures, response to, 267 Knee Immunoadsorption, severe RA with chronic hepatitis B, clinical arthroplasty, preoperative predictors of locomotor ability fol- improvement with protein A immunoadsorption, 722 lowing, 36 895 Knee (cont’d) Measuring instruments (cont’d) Knee Injury and Osteoarthritis Outcome Score (KOOS), S67 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), OA, exercise effects on outcome, mechanical environment and, S197 255 Bath Ankylosing Spondylitis Functional Index (BASFI), 483, OA, isometric muscle force measurement, 29 $197 OA, muscle dysfunction and effective rehabilitation, 444 Bath Ankylosing Spondylitis Global Score (BAS-G), S197 OA, vertebral and nonvertebral fractures in the elderly, 648 Bath Ankylosing Spondylitis Metrology Index (BASMI), S197 Knee Injury and Osteoarthritis Outcome Score (KOOS), S67 Beck Depression Inventory (BDI), S134 Knowledge of disease, RA, quality of life related to, 221 Behavioral Risk Factor Surveillance System (BRFSS), 658 Berg Balance Scale, S28 British Isles Lupus Assessment Group (BILAG), S225 L Cedars-Sinai Health-Related Quality of Life Instrument, 78, 798 Child Health Assessment Questionnaire (CHAQ), S5 Leflunomide, RA, safe use in clinical practice, 745 Children’s Arthritis Self-Efficacy Scale (CASE), S147 Life Satisfaction Index-A (LSI-A), S165 depression and depressive symptoms, 549, S134 Loading Disabilities of the Arm, Shoulder, and Hand (DASH), S50 joint structures, response to immobilization and remobilization, disability assessment using performance in the home, 640 267 Disease Activity Score (DAS), 7, S214 in models of joint disease, 239 OA, exercise effects on knee OA outcome, mechanical environ- Disease Repercussions Profile (DRP), S113 ment and, 255 Dougados Functional Index (DFI), $197 Local loading, joint disease models and, 239 Dynamic Gait Index (DGI), S28 Locomotor ability, following total knee arthroplasty, preoperative European Consensus Lupus Activity Measurement (ECLAM), predictors, 36 335, S225 Low back pain EuroQoL, S113 acute low back pain (ALBP), self-management program for, 179 fatigue, S113, S175 measures of back function, S43 Fatigue Questionnaire, $175 Lower extremity function, measures of, $67 Fatigue Scale, S175 Lungs. See Pulmonary disease Fibromyalgia Impact Questionnaire (FIQ), S210 Lupus erythematosus. See Systemic lupus erythematosus; Tumid FM measures, S210 lupus erythematosus Foot Function Index (FFI), S67 Lymphoma Functional Assessment System (FAS), S67 Hodgkin’s lymphoma presenting as Tietze’s syndrome, 737 Gait Velocity test, S28 SS, improvement in following rituximab therapy for marginal General Health Questionnaire (GHQ-12), S165 zone lymphoma, 394 Generalized Self-Efficacy Scale (GSES), S147 Geriatric Depression Scale (GDS), $134 Grip Ability Test (GAT), S59 M Harris Hip Score (HHS), S67 Health Assessment Questionnaire (HAQ), S15, 784 MACTAR Patient Preference Disability Questionnaire, $15 Health Assessment Questionnaire for the Spondylarthropathies Malignant hyperthermia, rhabdomyolysis and myalgia with anti- (HAQ-S), S197 cholesterolemic treatment as sign of susceptibility to, 237 Hospital Anxiety and Depression Scale (HADS), S134 Marginal zone lymphoma, SS, improvement in following ritux- Index of Severity for Hip Osteoarthritis (ISH), S67 imab therapy, 394 Index of Severity for Knee Osteoarthritis (ISK), S67 Mass spectrometry, OA or RA, bacterial components in synovial Insomnia Severity Index, S184 tissue, 328 Jebsen Test of Hand Function, S59 Mastery Scale, S147 Juvenile Arthritis Functional Assessment Report (JAFAR), S5 McGill Questionnaire (MPQ), S96 Juvenile Arthritis Functional Assessment Scale (JAFAS), S5 Measurement, of isometric muscle force by clinicians in knee OA, Juvenile Arthritis Functional Status Index (JASI), S5 29 Juvenile Arthritis Quality of Life Questionnaire (JAQQ), S105 Measuring instruments juvenile DM, validity and reliability of Disease Activity Score Activities of Daily Living Scale of the Knee Outcome Survey for children, 7 (ADLS), S67 Katz Index of Activities of Daily Living, S15 adult back and neck function, S43 adult general functional status, $15 Knee Injury and Osteoarthritis Outcome Score (KOOS), S67 adult general performance tests, S28 Life Satisfaction Index-A (LSI-A), S165 adult hand function, S59 MACTAR Patient Preference Disability Questionnaire, S15 adult lower extremity function, S67 Mastery Scale, $147 adult measures of pain, S96 McGill Questionnaire (MPQ), S96 adult quality of life, S113 Medical Outcomes Study (MOS) Sleep Scale, $184 adult shoulder function, S50 Modified Health Assessment Questionnaire (MHAQ), S15 adult work disability, S85 Multi-Dimensional Health Locus of Control Scale (MHLC), Affect Balance Scale (ABS), S165 $147 American Academy of Orthopedic Surgeons Lower Limb Ques- Multidimensional Assessment of Fatigue Scale, $175 tionnaire, S67 NASS Lumbar Spine Outcome Assessment Instrument, S43 American Shoulder and Elbow Surgeons Standardized Shoul- Neck Disability Index, S43 der Form, S50 Nottingham Health Profile, $113 Ankylosing Spondylitis Quality of Life (ASQOL), $197 OA, content validity of timed tests, 535 Arthritis Hand Function Test (AHFT), S59 OA, Quality of Well-Being Scale, 23 Arthritis Helplessness Index (AHI)/Rheumatology Attitudes In- Oswestry Low Back Pain Disability Index, S43 dex (RAI), S147 Pain Behavior Observation Method, S90 Arthritis Impact Measurement Scales (AIMS/AIMS2), S113 Pain Coping Questionnaire (PCQ), S90 Arthritis Self-Efficacy Scale (ASES), $147 Parent’s Arthritis Self-Efficacy Scale (PASE), S147 AS measures, 483, S197 Patient Generated Index (PGI), S113 Barthel Index, S15 for pediatric function, S5 896 Measuring instruments (cont’d) Measuring instruments (cont’d) Pediatric Orthopedic Surgeons of North America (POSNA) Pe- Verbal Descriptive Scale (VDS), S96 diatric Musculoskeletal Functional Health Questionnaire, S5 Visual Analog Scale (VAS), S96 Pediatric Pain Questionnaire (PPQ), S90 West Haven-Yale Multidisciplinary Pain Inventory (WHYMP)I), Pediatric Quality of Life (PedsQL), $105 S96 Physical Performance Test (PPT), S28 Western Ontario and McMaster Universities Osteoarthritis In- Pittsburgh Sleep Diary, S184 dex (WOMAC), S67 Pittsburgh Sleep Quality Index (PSQI), S184 Work Limitations Questionnaire (WLQ), S85 Primary Care Evaluation of Mental Disorders-Mood Module World Health Organization’s Quality of Life Instruments, $113 (PRIME-MD), S134 See also Assessment psychological well-being, S134, S165 Meclofenamate, dyspepsia and, meta-analysis, 508 Quality of Well-Being Scale (QWB), 23, S113 Medical costs Quebec Back Pain Disability Scale, S43 of arthritis, 101 RA, affective disorder in: receiver operator characteristic ana- health care utilization among older adults with arthritis, 164 lysis, 368 OA, socioeconomic impact of, in Hong Kong, 526 RA, Cedars-Sinai Health-Related Quality of Life Instrument, 78, RA, costs and cost predictors, in Spain, 64 798 Medical Outcomes Study (MOS) Sleep Scale, S184 RA, CES-D for assessing depression, 368, 549 Methotrexate (MTX) RA, Endler Multidimensional Anxiety Scales (EMAS), 368 PsA, efficacy of infliximab with MTX in resistant PsA, 541 RA, health-related quality of life patient questionnaires in clin- RA, hepatitis C and MTX, 843 ical practice, 574 RA, pneumonitis after initiation of therapy, 617 RA, measures for, S214 Microbes, in the joints, 479 RA, Positive and Negative Affect Schedule, 368 Microscopic polyangiitis (MPA) RA, quality of life related to social support and disease knowl- first signs of, 709 edge in women, 221 with poor prognosis factors, treatment with glucocorticoids and RA, self-report questionnaires in clinical practice, 59 cyclophosphamide pulses, 93 RA, validation of satisfaction questionnaire for multidisci- primary systemic vasculitides in Spain, epidemiology, 388 plinary care, 193 Mitral valve disease, with RA, 866 RA, Valspar 9 Whole Body Range of Motion Work Sample test, Moberg pickup test, 626 71 Mobility assessment, Tinetti Performance-Oriented Mobility As- RA, Work Instability Scale (WIS), 349 sessment (POMA), S28 Rapid Assessment of Disease Activity in Rheumatology (RA- Models DAR), S214 disability models, exercise and physical activity interventions RAQoL, S113 and, 114 Revised Leeds Disability Questionnaire, S197 joint disease models, loading and, 239 Rheumatoid Arthritis Disease Activity Index (RADAI), S214 Modified Health Assessment Questionnaire (MHAQ), S15 Rheumatoid Arthritis Pain Scale (RAPS), S96 Monarthritis, fatigue fractures suggesting, 741 Rheumatoid Arthritis Self-Efficacy Scale (RASE), S147 Mood, primary systemic vasculitis, quality of life and psycholog- Rheumatoid Arthritis Work Instability Scale (RA-WIS), S85 ical adjustment in, 826 Rheumatoid Hand Functional Disability Scale, S59 Morbidity, SLE, participatory patient-physician communication Roland-Morris Low Back Pain Measure, S43 and, 810 Rosenberg Self-Esteem Scale, S165 Multi-Dimensional Health Locus of Control Scale (MHLC), S147 Satisfaction with Life Scale (SWLS), S165 Multidimensional Assessment of Fatigue Scale, $175 Self-Administered Comorbidity Questionnaire (SCQ), 156 Multidisciplinary team care, RA, validation of satisfaction ques- self-efficacy, helplessness, mastery, and control, $147 tionnaire for, 193 Self-Efficacy Scale (SES), S147 Multiorgan dysfunction, ANCA in patients with, 151 Short Form-36 (Energy/Fatigue) Subscale of the Short Form Murine models, anti-TGF-f treatment and skin and lung fibrosis Health Survey, S113, $175 in sclerodermatous graft-versus-host disease, 611 Short-Form McGill Pain Questionnaire (SF-MPQ), S96 Muscle dysfunction, knee OA, rehabilitation and, 444 Shoulder Disability Questionnaire, S50 Muscle function, SS, physical capacity in, 681 Shoulder Pain and Disability Index (SPADI), S50 Muscle strength, recent-onset RA, strength training and physical Sickness Impact Profile (SIP), S113 function and working capacity, 71 Simple Shoulder Test, S50 Muscles SIP-RA, $113 colchicine myopathy in familial Mediterranean fever, 614 SLE, European Consensus Lupus Activity Measurement exercise and physical activity in children, benefits of, 435 knee OA, dysfunction and effective rehabilitation, 444 (ECLAM), 335 knee OA, isometric muscle force measurement, 29 SLE measures, S225 Musculoskeletal system sleep measures, S184 chronic upper extremity pain and co-occurring symptoms, 697 Stanford Health Assessment Questionnaire, validation of Japa- resultant and local loading in joint disease models, 239 nese version of, 784 Myalgia, with anticholesterolemic treatment, malignant hyper- State-Trait Anxiety Index (STAI), S165 thermia susceptibility and, 237 Systemic Lupus Activity Measure (SLAM), S225 Systemic Lupus Erythematosus Disease Activity Measure (SLE- DAI), $225 N Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index (SLICC/ACR-DI; NASS Lumbar Spine Outcome Assessment Instrument, S43 SDI), S225 National Arthritis Action Plan, implementation, 471 Timed Chair Stand Test, S28 Neck Disability Index, S43 Timed Up and Go Test, S28 Neck function, measures of, S43 Tinetti Performance-Oriented Mobility Assessment (POMA), Neovascularization, around optic nerve in GCA, 737 $28 Nitrate medications, OA, use of and new radiographic findings in Trust in Physician Scale with rheumatic disease patients, 51 hip OA in older women, 752 Valspar 9 Whole Body Range of Motion Work Sample test, Nonsteroidal antiinflammatory drugs (NSAIDs), meta-analysis of strength training in recent-onset RA, 71 dyspepsia and, 508 897 North American Spine Society (NASS) Lumbar Spine Outcome Assessment Instrument, S43 Nottingham Health Profile, S113 Pain Nucleolar phosphoprotein B23, autoantibodies against B23 in adult measures of, S96 SSc, associated with pulmonary hypertension, 85 AS measures, $197 Numbness, chronic upper extremity pain and co-occurring symp- chronic upper extremity pain and co-occurring symptoms, 697 toms, 697 FM, assessment, S210 FM, operant behavioral treatment, 314 in juvenile arthritis, 272 O measures of adult back and neck function, $43 measures of adult hand function, S59 Occupational risk, predicting onset of forearm pain, 519 measures of adult lower extremity function, S67 Older adults measures of adult quality of life, S113 arthritis, health care utilization and, 164 measures of adult shoulder function, S50 OA, cost effectiveness of COX-2 inhibitors, 283 measures of adult work disability, S85 OA, knee OA and vertebral and nonvertebral fractures, 648 pediatric measures of pain, S90 OA, nitrate medication use and new radiographic findings in pediatric measures of quality of life, S105 hip OA, 752 primary systemic vasculitis, quality of life, psychological ad- OA, quality of well-being in, 23, $113 justment and, 826 RA, cost effectiveness of COX-2 inhibitors, 283 RA measures, S96, S214 rehabilitation perspectives on compensatory mechanics in gait, SLE measures, $225 248 Pain Behavior Observation Method, S90 Oligoarthritis, family history of psoriasis and oligoarticular JIA, Pain Coping Questionnaire (PCQ), S90 488 Pan-bacterial polymerase chain reaction (PCR), OA or RA, bacte- Operant treatment, in FM, 314 rial components in synovial tissue, 328 Organ damage Parent’s Arthritis Self-Efficacy Scale (PASE), S147 juvenile-onset SLE, assessment of, 501 Patient education SLE, participatory patient-physician communication and, 810 hip dysfunction, outcome of “hip school,” 321 SSc, severe organ involvement in SSc with diffuse scleroderma, RA, group education for patients and partners, 556 606 RA, value of, 738 Orthopedic surgery, RA, declining use in, 216 Patient Generated Index (PGI), S113 Oslo-Truto-Amsterdam (OSTRA) Collaborative Study, RA, dam- Patient perceptions, of SSc, 689 age associated with low BMD and vertebral deformities, 209 Patient-physician communication, morbidity in SLE and, 810 Osteoarthritis (OA) Patient trust, use of Trust in Physician Scale, 51 bacterial components in, 328 Pediatric Orthopedic Surgeons of North America (POSNA) Pedi- costs of arthritis, 101 atric Musculoskeletal Functional Health Questionnaire, S5 COX-2 inhibitors, cost effectiveness of, 283 glucosamine therapy, current status, 601 Pediatric Pain Questionnaire (PPQ), S90 health-related quality of life measure in clinic population, 658 Pediatric Quality of Life (PedsQL), S105 hip, nitrate medication use and new radiographic findings in Pediatrics. See Children; Juvenile arthritis; Juvenile dermatomy- older women, 752 ositis; Juvenile idiopathic arthritis; Juvenile-onset systemic hip, sporting activity and development of, 228 lupus erythematosus; Juvenile rheumatoid arthritis hip dysfunction, outcome of “hip school,” 321 Perceptions, SSc, patients’ perceptions of, 689 knee, exercise effects on outcome, mechanical environment Performance-related measures, relationship between self-report and, 255 and, 535 knee, isometric muscle force measurement for, 29 Pharmacoeconomics, OA or RA, cost effectiveness of COX-2 in- knee, muscle dysfunction and effective rehabilitation, 444 hibitors, 283 knee, preoperative predictors of locomotor ability following Physical activity total knee arthroplasty, 36 Arthritis Foundation community-based programs, 463 knee, vertebral and nonvertebral fractures in the elderly, 648 children with arthritis, benefits of, 435 quality of well-being in older patients, 23 community-based physical activity intervention, 455, 463, 471 self-report and performance-related measures, relationship be- correlates of, 136 tween, 535 disability models, physical activity interventions and, 114 socioeconomic impact of, in Hong Kong, 526 National Arthritis Action Plan implementation, 471 Trust in Physician Scale, use, 51 physical activity levels in US population with and without walking aids, possession and use of, 838 arthritis, 129 Osteoporosis public health benefits of, 122 hip OA, nitrate medication use and new radiographic findings Work Group Recommendations: 2002 Exercise and Physical in older women, 752 Activity Conference (St. Louis), 121, 141, 261, 280, 453, 477 RA, OSTRA Study, 209 See also Exercise RA, vertebral deformities and BMD, 209, 355 Physical capacity, in SS, 681 update in, 732 Physical function Oswestry Low Back Pain Disability Index, S43 in AS, 483 Outcomes disability models, 114 complementary therapies and, 619 recent-onset RA, effect of strength training, 71 hip dysfunction, outcome of “hip school,” 321 Physical Performance Test (PPT), S28 HIV-associated PM, 172 Physician specialty, coxibs, use and discontinuation influenced OA, exercise effects on knee OA outcome, mechanical environ- by, 293 ment and, 255 Physicians OA, quality of well-being in older patients, 23 redesigning rheumatology practice, 716 RA, impact of socioeconomic status on course of, 567 SLE, participatory patient-physician communication and mor- RA, sE-selectin for stratifying outcome, 546 bidity, 810 SLE, participatory patient-physician communication and mor- Trust in Physician Scale, use of, 51 bidity in, 810 Piroxicam, dyspepsia and, meta-analysis, 508 SSc, fibrosing alveolitis in and outcome, 610 Pittsburgh Sleep Diary, S184 898

See more

The list of books you might like

Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.
DMCA & Copyright: Dear all, most of the website is community built, users are uploading hundred of books everyday, which makes really hard for us to identify copyrighted material, please contact us if you want any material removed.
Copyright @ PDFdrive.to, 2022 | We love our users